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5ABSTRACT
The purpose of the present study was to extend our knowledge of the occurrence, characteristics 
and prognosis of uveitis in patients with juvenile idiopathic arthritis (JIA: arthritis of unknown 
cause of at least six weeks' duration in a child under 16 years of age). 
The occurrence of uveitis was examined retrospectively in subjects entitled under the 
nationwide sickness insurance scheme to receive specially reimbursed medication for JIA in 
5/21 central hospital districts in Finland (population basis about 1 300 000 inhabitants) during 
1980, 1985 and 1990. A total of 114 children with JIA were found and uveitis was diagnosed in 
16% of them. Uveitis was chronic (duration >6 months) in nine cases, the most severe cases 
being those three in whom uveitis was detected at the onset of arthritis. 
In 49 sibling pairs with JIA from the Rheumatism Foundation Hospital uveitis was detected in 
26%. These 80 familial JIA cases belonging to 37 families with two or three affected siblings 
were collected from about 2000 children seen at the Hospital during 15 years. The observed 
concordance rate for uveitis (three pairs) did not differ from that expected (3.4 pairs). Uveitis 
was chronic in most instances, but its course was usually mild. 
In the clinic-based cohort of 426 patients with newly diagnosed JIA from the Rheumatism 
Foundation Hospital the most important determinants of associated uveitis were early onset of 
arthritis (at the age of 2 to 4 years) and antinuclear antibody (ANA) positivity. During the mean 
follow-up time of 4.5 years a total of 104 (24%) children with JIA developed uveitis. The 
condition was in most cases (99 out of 104) asymptomatic and was found early in the disease 
process, in a majority of cases during the first four years from the onset of arthritis. 
Proportionally uveitis was as frequent in rheumatoid factor-seronegative polyarthritis as in 
oligoarthritis and there was no predominance of girls. The prognosis of uveitis in this 
prospective series was better than that in most earlier reports; complications in 24% of cases, 
none of the patients became blind. 
In the above cohort, 372 children had seronegative oligoarthritis or polyarthritis. Within this 
group, the activity of arthritis was compared between patients with associated uveitis and 
6without it. The erythrocyte sedimentation rate was significantly higher at the diagnosis of 
arthritis and at the end of follow-up in 96 JIA patients with uveitis than in the 276 without. The 
hemoglobin value was significantly lower at the diagnosis of arthritis in patients with uveitis, 
but not at the end of follow-up. The number of inflamed joints was significantly greater at the 
end of the follow-up in patients with persistent polyarthritis and uveitis compared to those 
polyarthritis patients without uveitis. Patients with uveitis were significantly more often treated 
with oral prednisolone, glucocorticoid injections and methotrexate compared to patients without 
uveitis. Clinical remission of arthritis was achieved significantly less frequently in patients with 
uveitis than in those without. The inflammatory activity of arthritis would thus appear to be 
increased in patients with JIA and uveitis compared to those without uveitis. 
A report of a patient with juvenile-type chronic polyarthritis and late-onset severe chronic 
uveitis controlled with prednisolone, cyclosporin A and methotrexate is included in the series. 
The successful treatment was carried out in close co-operation with rheumatologists. 
In a study based on the Finnish Register of Visual Impairment arthritis or a comparable 
condition was found as the etiology in 22% of the 174 patients with severe uveitis leading to 
visual impairment during 1980-1996. The greatest single group in this series comprised patients 
with JIA, 8%, followed by spondyloarthropathy 6%, sarcoidosis 3% and seronegative 
rheumatoid arthritis 2%. Legally specified blindness was documented in 65 of 174 patients, 
including eight persons totally blind. Overall, uveitis led to visual impairment within a mean 
period of 18 years. 
In some patients the treatment of chronic uveitis associated with JIA is difficult, and in such 
cases the collaboration of ophthalmologists and pediatric rheumatologists/rheumatologists is 
essential in determining the optimal management early in the disease course. 
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1. INTRODUCTION 
Juvenile idiopathic arthritis (JIA) is defined as an arthritis of unknown cause of at least six 
weeks' duration commencing before the 16th birthday (Petty and Southwood 1998). Several 
subgroups of JIA are well recognised, differing according to clinical manifestations, prognosis, 
specific autoimmune features and genetic determinants. The three major subgroups 
distinguished during the first six months of arthritis are oligoarthritis (1 to 4 joints involved), 
polyarthritis (≥5 joints afflicted), and systemic onset JIA (with fever and papulomacular rash at 
the onset). 
Ethnic differences exist with regard to occurrence rates and distributions according to 
subgroups and gender. In Western societies the annual incidence of JIA is 10-20/100 000 in the 
pediatric population. Mono- and pauciarticular types of onset predominate, comprising about 50 
to 75% of these patients. The proportion of polyarthritis is estimated to be 20 to 40%. Systemic 
onset JIA is less common; it is detected in 3 to10%. The variation in the proportions of the 
different subgroups depends in part on the study material: population- or clinic-based. Children 
with JIA are frequently positive for antinuclear antibodies (ANA). 
A frequent extra-articular manifestation of JIA is chronic asymptomatic uveitis, which is found 
in about 20% of children with JIA during the first seven years of the disease. The risk of 
insidious uveitis is greatest in ANA-positive girls with early onset oligoarthritis. The 
male:female ratio in patients with JIA-associated uveitis is about 1:5. The routine screening of 
JIA patients 2 to 4 times a year for the detection of silent uveitis was recommended three 
decades ago. Although the prognosis of uveitis is improving, due to prompt treatment with 
topical corticosteroids and mydriatics and in severe cases with immunosuppressive agents and 
to advances in surgical treatment of complications (cataract and glaucoma), 6 to 12% of these 
children nevertheless become visually handicapped (Kanski 1990). A great challenge to 
ophthalmologists and pediatric rheumatologists is how to save the sight of these children 
(Nguyen and Foster 1998). 
The impulse to the present study arose from everyday work among children with JIA-associated 
uveitis: to widen our knowledge of its occurrence, characteristics and prognosis. 
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2. REVIEW OF THE LITERATURE 
2.1. Juvenile idiopathic arthritis 
2.1.1. Nomenclature and classification 
George Frederic Still published his classic description of chronic arthritis in children in 1897 
(Still 1897). In the early years juvenile arthritis was called Still's disease; nowadays this term is 
reserved and sometimes used for the systemic form of JIA and also for the similar systemic 
arthritis starting in rare cases in adulthood (Wood 1978, Andersson Gäre 1999). 
The term juvenile idiopathic arthritis is used for persistent joint inflammation or systemic 
illness with fever and rash of unknown cause lasting at least six weeks and starting in a child 
under 16 years of age (Petty and Southwood 1998). The criteria of the European League 
Against Rheumatism (EULAR) (Wood 1978) are widely applied in Europe and the disease is 
named juvenile chronic arthritis, whereas in the United States idiopathic childhood arthritis is 
called juvenile rheumatoid arthritis according to the American Rheumatism Association's 
(ARA, nowadays named the American College of Rheumatism, ACR) criteria (Brewer et al 
1977). Recently, a new set of criteria was published by the International League Against 
Rheumatism (ILAR), covering all idiopathic childhood arthritides under the name of juvenile 
idiopathic arthritis (Petty and Southwood 1998).  
The three main sets of criteria for childhood chronic arthritis of unknown cause are presented in 
Table 1. In the present work the term JIA was used throughout, although in some instances this 
will result in minor discrepancies. 
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Table 1. The three main sets of criteria for childhood chronic arthritis 
 EULAR ARA ILAR 
Name for the disease group Juvenile chronic 
arthritis (JCA) 
Juvenile rheumatoid 
arthritis (JRA) 
Juvenile idiopathic 
arthritis (JIA) 
JAS, JPsA, IBD included 
(separately listed) 
excluded included 
Duration of joint symptoms 
necessary for the diagnosis of 
arthritis 
3 months 6 weeks 6 weeks 
Age of the patient at disease 
onset
0-15 years 0-15 years 0-15 years 
Exclusion of other diseases yes yes yes 
Definition of subtypes at 6 
months' disease duration 
yes yes yes 
Abbreviations: JAS, juvenile ankylosing spondylitis; JPsA, juvenile psoriatic arthropathy;  
IBD, arthropathy associated with inflammatory bowel disease. 
According to the ILAR criteria, JIA is divided into seven subtypes after six months' disease 
duration:
Pauciarthritis (also named oligoarthritis), involving 1 to 4 joints, is the most common type of 
JIA, comprising 50 to 70% of JIA patients; pauciarthritis is further divided into persistent 
pauciarticular arthritis and extended oligoarthritis, i.e. arthritis with pauciarticular onset and 
polyarticular course. 
In polyarthritis five or more joints are inflamed; the condition comprises rheumatoid factor 
(RF)-negative and RF-positive polyarthritis; 20 to 40% of JIA cases belong to the polyarthritis 
group and the great majority of these are RF-negative. 
Systemic onset-type JIA is diagnosed in about 3 to 10% of JIA patients. It initially manifests 
with fever and typical papulomacular rash; subsequently the children develop arthritis. 
14
Enthesitis-related arthritis patients are often boys of the age of 10 or over, in many cases HLA 
B27- positive; they may have acute anterior uveitis (AAU) and may later develop a disease 
resembling adult spondyloarthropathy.  
Psoriatic arthritis presents with typical psoriatic skin and/or nail involvement and joint 
symptoms. 
Other types of arthritis include for example arthropathy associated with inflammatory bowel 
diseases (Petty and Southwood 1998). 
The division of the disease into distinct subgroups is relevant in that these differ in their course 
and prognosis, and probably also in their etiological background. JIA is not limited to the joints; 
patients may have a variety of extra-articular manifestations. In the systemic type of JIA the 
general symptoms predominate, especially at the onset of the disease. Fever, often of lesser 
degree, is also a common feature in the other subtypes; in addition, lymphadenopathy, 
pericarditis and anemia are seen. Uveitis is nevertheless the most common extra-articular 
manifestation of JIA (John and John 1984, Cassidy et al 1989). 
Two different kinds of uveitis are detected in JIA: AAU, which frequently accompanies HLA 
B27-associated disease, and insidious chronic anterior uveitis (CAU), which occurs most 
frequently in ANA- positive girls with early-onset oligoarthritis (beginning of arthritis before 
the age of eight years). 
The main characteristics of patients belonging to the most common onset types of JIA are 
shown in Table 2 (John and John 1984, Cassidy et al 1989, Cassidy 1993). 
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Table 2. Specific characteristics of patients in the main onset types of juvenile idiopathic 
arthritis 
 Oligoarthritis Polyarthritis Systemic onset arthritis 
Number of joints involved <5 ≥5 variable
Sex ratio (male/female) 1:4 1:3 1:1 
Chronic uveitis 20% 5% rare 
ANA-positive 50% 20% 10% 
RF-positive rare 15% rare 
2.1.2. Occurrence 
The published data on the incidence and prevalence of JIA are somewhat difficult to compare 
by reason of the heterogeneity of the disease, differences in the classification criteria, the nature 
of the study material, and case ascertainment. Ethnic and geographical factors as well as 
seasonal variations in the occurrence of JIA have been observed (Andersson Gäre et al 1987, 
Andersson Gäre and Fasth 1992, Oen and Cheang 1996, Andersson Gäre 1999).  
The prevalence of JIA in areas where reliable data are available has been estimated to be about 
0.1% in the pediatric population, and its annual incidence has varied from 10 to 20/100 000 
(Towner et al 1983, Kunnamo et al 1986, Oen and Cheang 1996, Andersson Gäre 1999). The 
incidence studies from Europe and North America predominantly involve populations of North 
European ancestry. The highest reported rates are from the Scandinavian countries and a 
tendency toward a falling north- to south gradient has been noted in Europe (Andersson Gäre 
1999). No such gradient seems to exist in North America.  
Recently, a JIA incidence of 14/100 000 was reported in the Finnish pediatric population <16 
years old (Kaipiainen-Seppänen and Savolainen 1996). Accordingly, it can be estimated that 
there are about 150 new cases of JIA in Finland each year. In different community-based 
studies from Finland, 66 to 76% of children with JIA have been found to have oligoarthritis, 18 
to 31% polyarthritis, and only 3 to 6% systemic onset JIA (Lantto and von Wendt 1985, 
Kunnamo et al 1986, Kaipiainen-Seppänen and Savolainen 1996).
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2.1.3. Autoantibodies 
Many immunological abnormalities have been found in children with various forms of chronic 
arthritis, but few are clinically useful or well understood (Leak 1988, Lawrence et al 1993). It is 
important, however, to distinguish patients with ANA and RF. 
The most common immunological abnormality in JIA is positive ANA, which usually exhibits 
a homogeneous or speckled pattern in the indicator cell. The frequency of positive reactions 
depends on the test techniques adopted. On average, ANA has been detected by 
immunofluorescence in roughly 30% of children with JIA, most frequently in patients with 
oligoarthritis, less so in those with RF-negative polyarthritis and only seldom in the other 
subtypes of JIA. Interestingly, ANA-positive patients have a clearly increased risk of uveitis 
(Leak et al 1986). The underlying reason for this association is not known. 
Specific components of nuclei have been identified as the antigens for the ANA reaction in 
patients with systemic lupus erythematosus and certain other systemic rheumatic diseases. 
Antibodies against these components do not occur in patients with JIA; the nature of the 
antigen(s) responsible for positive ANA in JIA patients has not yet been settled with any 
certainty (Leak 1988, Lawrence et al 1993). 
RF as determined by conventional test techniques occurs only seldom in patients with JIA. 
Those children who do have a persistent high-titred RF quite obviously have genuine 
rheumatoid arthritis (RA), which has its onset in childhood. Attention has been drawn to the 
occurrence of so-called hidden RF, i.e. RF blocked by autologous immunoglobulin G (IgG), in 
other forms of JIA (Lawrence et al 1993), but there seems to be no unanimity as to the validity 
of these findings. 
In patients with RA a number of other autoantibody systems are present which have been 
claimed to be specific enough to serve as diagnostic and prognostic markers of this disease 
(Goldbach-Mansky et al 2000). Very little information is available concerning the occurrence 
of these marker antibodies in JIA. 
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Autoantibodies against soluble bovine retinal S protein may be linked to ocular damage in 
patients with JIA, since children with JIA-associated uveitis have been reported to have higher 
antibody levels compared to those without eye disease and to normal controls (Petty et al 1987). 
2.1.4. Etiological and genetic aspects 
As pointed out above (2.1.1.), the term JIA covers a number of different disease entities. RF-
positive polyarthritis, psoriatic arthritis and enthesitis-related arthritis have their counterparts 
among adults (2.1.6.). The risk factors and the genetic background of these entities will not be 
discussed in this review. 
The subtypes of JIA occurring predominantly and also most frequently in children are systemic 
arthritis, oligoarthritis and RF-negative polyarthritis. As previously pointed out, systemic 
arthritis may occur in adults (adult-onset Still's disease) and a genetic link has been proposed 
between JIA and adult RF-negative polyarthritis (Gao et al 1991). The latter observation may 
be taken to mean that some cases of adult RF-negative RA represent an adult counterpart to 
juvenile polyarthritis. 
Substantial variation in the occurrence of JIA over extended (secular trends) and shorter 
(seasonal variation) periods has been described in some studies (Andersson Gäre 1999, Glass 
and Giannini 1999), suggesting the implication of environmental triggers. Even more clear-cut 
clusters have been reported, particularly in one study from England in which there was an 
accumulation of JIA cases associated with influenza A infection (Pritchard et al 1988). In 
Finland, the incidence of JIA remained the same during the years 1980, 1985 and 1990, 
whereas a significant increase in number of cases and their spatial clustering was noted in 1995 
(Kaipiainen-Seppänen and Savolainen 2001). In this regard it is worth noting that the epidemic 
of Lyme arthritis in Connecticut was initially regarded as an unusual cluster of JIA (Steere et al 
1977).
Some family aggregation and a few monozygotic twin pairs concordant for JIA have been 
described (Silman and Hochberg 1993, Glass and Giannini 1999), suggesting the involvement 
of genetic factors. Since, however, virtually no information is available regarding the basic JIA 
population from which these cases were derived, it is not possible to draw conclusions 
concerning the magnitude of the genetic component. Very recently, 41 multicase families with 
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88 siblings afflicted with JIA were found in a Finnish patient population of about 2000 
(Savolainen et al 2000). In view of the population prevalence of the disease (1 per 1000), the 
figures would indicate that the sibling recurrence ratio (probably the best indicator of the 
magnitude of the genetic component) is fairly high, certainly higher than in adult RA. 
Accumulating data indicate significant associations between particular HLA (human leukocyte 
antigen) alleles and certain forms of JIA (Donn and Ollier 1996, Glass and Giannini 1999). 
There may be difficulties in comparison of different studies; e.g. patient inclusion criteria have 
not been uniform. Certain general conclusions can be drawn: 
a) The HLA allele distributions differ between patients with systemic disease, oligoarthritis and 
RF negative polyarthritis. 
b) Several different alleles can be involved. In some instances this is due to close linkage of the 
alleles, but totally independent susceptibility alleles may equally exist. 
c) The HLA alleles operating in JIA can contribute to an increased risk only during a certain 
age interval and be neutral or even protective at other times (Murray et al 1999). 
d) There may be ethnic differences in HLA associations. 
The relative risk conferred by certain HLA allele combinations can be quite high. Nonetheless 
the established HLA associations explain merely a part, perhaps only a small part, of the overall 
genetic background of JIA. Progress in molecular genetics has provided means for genome 
wide screening, offering prospects to identifying new susceptibility loci outside the HLA region 
( Glass and Giannini 1999). 
2.1.5. Treatment 
Treatment of JIA is multidisciplinary (orthopedics, physiotherapy etc.) but the study described 
here concentrates on drug therapy. The immediate purpose of treatment is to control the disease 
and the ultimate goal is to prevent disability and premature death.  
Nonsteroidal anti-inflammatory drugs (NSAIDs) together with intra-articular corticosteroid 
injections are widely used at the onset of arthritis. Of disease modifying antirheumatic drugs, 
hydroxychloroquine, gold salts and sulfasalazine alone or in combinations are included in the 
treatment regimen if NSAIDs are not sufficiently effective. During the last 10 years gold has 
frequently been replaced by methotrexate. In refractory cases of arthritis and uveitis the 
19
treatment is reinforced by corticosteroids, other immunosuppressive or immunomodulatory 
drugs such as cyclosporine and azathioprine. Rarely, even chlorambucil and cyclophosphamide 
are considered for medication in the most severe cases, above all in amyloidosis (Rosenbaum 
1994, Savolainen and Ylijoki 1995, Savolainen 1999). Local treatment with intra-articular 
steroid injections plays a central role in current practice in pediatric arthritis and is safe and 
effective (Cassidy 1993). 
Once remission is achieved, the medication is gradually tapered down over a period of months 
and years and the treatment is discontinued drug by drug, taking into account the clinical status 
of the child. 
2.1.6. Course of juvenile idiopathic arthritis in the main subgroups 
As mentioned above, the most common subtype of JIA is oligoarthritis, also called 
pauciarthritis. It affects mainly girls and has its peak incidence at the age of three years. The 
joints usually involved are knees, wrists and ankles, including subtalar joints. In one third or a 
half of patients the joint inflammation begins in one single joint. This type of JIA is commonly 
associated with uveitis, and ANA-positivity is a frequent finding. The articular prognosis in this 
disease subtype is often good; remission frequently occurs in 4 to 5 years (Cassidy 1993, Woo 
and Wedderburn 1998). Uveitis is common, occurring in about 20% of these children and 
consequently worsening the prognosis (Kanski and Petty 1996). 
If oligoarthritis eventually spreads to more than four joints it is termed extended oligoarthritis. 
This form of arthritis is often clinically indistinguishable from polyarthritis, and has the same 
kind of prognosis as polyarthritis (Cassidy et al 1986, Flatφ et al 1998). Methotrexate has been 
shown to be an effective treatment in these cases. 
RF-negative polyarthritis is often insidious at onset, with gradual development of progressive 
joint involvement. Large joints, typically knees, wrists, elbows and ankles are frequently first 
afflicted, but also the small joints in hands or feet can be involved, either early or late during the 
disease course. The pattern of joint involvement is often symmetric. An affection of the cervical 
spine occurs in half of the children with polyarticular JIA. Systemic manifestations of this 
subtype include low-grade fever, hepatosplenomegaly and lymphadenopathy. Chronic uveitis is 
found in about 5% of cases (Cassidy 1993, Kanski and Petty 1996, Woo and Wedderburn 
1998).
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RF-positive polyarthritis typically occurs in teenagers and can lead to widespread joint 
destruction. It is fairly rare, comprising about 3% of JIA patients in the UK and Finland. It is 
most likely RF-positive RA, having its onset at pediatric age, and uveitis occurs rarely in this 
subtype of JIA (Cassidy 1993, Kanski and Petty 1996, Woo and Wedderburn 1998). 
JIA begins with systemic symptoms in 3 to 10% of patients. The peak age of onset is two years, 
and boys and girls are equally affected. High spiking fever and maculopapular rash are 
hallmarks of the disorder (Cassidy 1993, Woo and Wedderburn 1998). Arthritis may appear 
concurrent with the onset of systemic signs or even months later. Prominent visceral 
involvement (hepatosplenomegaly, lymphadenopathy and pericarditis) may accompany this 
subtype. Children affected are often seriously ill and drug management remains unsatisfactory. 
On the other hand, about a half of the cases are mild and may clear up spontaneously; the 
symptoms are treated with NSAIDs. If long-term treatment with high-dose corticosteroids is 
necessary the result may be undesirable side-effects such as osteoporosis, growth retardation 
and cataract formation. According to most studies the systemic disease subtype predominates 
among patients with secondary amyloidosis (Stoeber 1981). Uveitis is uncommon (Kanski and 
Petty 1996). 
Enthesitis-related arthritis is believed to represent the childhood equivalent of the various 
forms of chronic spondyloarthropathies of adults. This is typically a disease of preteen and 
teenage boys, presenting as asymmetrical arthritis of the lower limbs and enthesitis. Most 
patients are positive for the HLA B27 allele and they frequently (in 5 to15% in juvenile SPA 
and in 2% in Reiter's syndrome) have recurrent attacks of AAU. Sulfasalazine is the 
recommended treatment in addition to NSAIDs and local glucocorticoid injections. The 
functional outcome is usually good (Kanski and Petty 1996, Woo and Wedderburn, 1998). 
Psoriatic arthritis frequently affects distal interphalangeal joints and patients may have 
polyarthritis involving large and small joints. In some cases the arthritis is highly erosive and 
difficult to manage. Chronic uveitis can occur in 10 to15% of these patients. It is frequently 
chronic and asymptomatic and may prove refractory (Cassidy 1993, Kanski and Petty 1996, 
Woo and Wedderburn 1998). 
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2.1.7. Complications 
Severe JIA can cause growth retardation and even arrest of growth. Local inflammatory activity 
in a joint can result in accelerated growth of the epiphyses in the affected joint, e.g. in the knee, 
causing unequal leg length. Premature closing of the epiphyseal growth plates is the underlying 
reason for abnormal shortness of the digits (brachydactyly) and undue shortness of the lower 
jaw (micrognathia) (Woo and Wedderburn 1998). In a study from the former East Germany the 
overall frequency of growth retardation was 20%, unevenly distributed over the main subgroups 
of JIA: 4% in oligoarthritis, 20% in polyarthritis, and as high as 46% in systemic onset arthritis 
(John and John 1984). 
The long-lasting uncontrolled inflammation in JIA patients carries the risk of amyloidosis, a 
fatal complication of the disease. In amyloidosis inert insoluble fibrillar material with starchlike 
staining properties accumulates in different organs. The mechanism is unknown; hereditary or 
other factors may be involved, since only a minority of patients develop the disorder and its 
geographical distribution is uneven. Typically, amyloidosis is suspected when proteinuria 
appears. The diagnosis is frequently confirmed by biopsy (e.g. from subcutaneous fat or 
gingiva) (Klemi et al 1987). In Finland, the rate of amyloidosis in one hospital based study was 
3% after a mean disease duration of 25 years (Ylijoki 1998). There is evidence that the 
incidence of amyloidosis in JIA is declining (Savolainen and Isomäki 1993, Savolainen and 
Ylijoki 1995). 
Osteopenia in JIA is associated with inflammatory activity, immobility or loss of function, and 
glucocorticoid therapy. Body size, physical activity and calcium intake are significant positive 
determinants of bone mineral density in JIA patients in the same manner as in healthy children 
(Kotaniemi 1997). 
Visual impairment in JIA is a consequence of chronic silent uveitis. This issue will be discussed 
in detail in a later section. 
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2.2. Uveitis  
Uveitis is a general term used for inflammation of the uveal tract (composed of iris, corpus 
ciliare and chorioidea i.e. the middle coat of the eye) due to any cause. It covers a large group 
of diverse diseases, which affect not only the uvea but also the retina and vitreous humor 
(Nussenblatt et al 1996). 
2.2.1. Anatomical criteria for uveitis 
The International Uveitis Study Group (IUSG, Bloch-Michel and Nussenblatt 1987) 
recommends classification of uveitis according to anatomical location as follows:
Anterior uveitis affects the iris and ciliary body as far back as the posterior limit of the pars 
plicata and it includes iritis, cyclitis and iridocyclitis.  
Intermediate uveitis affects the pars plana ciliaris and peripheral retina. The terms formerly 
used are pars planitis, posterior cyclitis, hyalitis, basal retinochoroiditis, peripheral exudative 
retinitis and peripheral uveitis. 
Posterior uveitis involves areas behind the posterior hyaloid membrane of the vitreous base. It 
can be focal, multifocal or diffuse. It includes choroiditis, chorioretinitis, retinochoroiditis and 
neurouveitis.
Panuveitis is a generalised inflammation of all three parts of the uvea. 
Anterior uveitis is the most common form of the disorder, comprising 50 to 60% of cases 
(frequently associated with HLA B27) (Saari 1984), followed by posterior uveitis in 20 to 30%, 
panuveitis in 10 to 20% and intermediate uveitis in about 10% of cases classified by location of 
the eye inflammation (Smit et al 1993, McCannel et al 1996, Rodriguez et al 1996). 
The onset of uveitis may be sudden or insidious, and the duration short (<3 months) or long
(chronic) (≥3 months). Its activity can be severe, mild or absent, the pattern of the disease 
single or repeated episodes, and uveitis can be unilateral or bilateral. It is classified as 
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exogenous when it is caused directly by some infective agent, or endogenous when it occurs de
novo without any obvious inciting agent (Forrester 1991). Endogenous uveitis has strong 
indirect links with infective agents implicated in its pathogenesis via several mechanisms, and 
the distinction between exogenous and endogenous uveitis has become blurred (Forrester 
1991). The pattern of uveitis can be granulomatous, with large cells and 'mutton-fat keratic 
precipitates' (e.g. in sarcoidosis) and non-granulomatous, with small to medium-sized cells in 
the anterior chamber and on the corneal endothelium (e.g. in JIA). 
2.2.2. Etiological classification 
Classification of uveitis by etiology includes infectious, non-infectious and idiopathic uveitis. 
The etiology of the condition varies in different populations and areas (Rosenbaum and Cousins 
1982, O'Brien et al 1994, Rodriguez et al 1996). The causative agents have changed over time: 
e.g. Treponema pallidum and Mycobacterium tuberculosis were regarded as the most frequent 
etiological factors in uveitis surveys before the 1950's, but at present these are rare etiological 
agents in immunocompetent patients in developed countries. Meanwhile new diseases have 
emerged, e.g. acquired immunodeficiency syndrome (Henderly et al 1987). 
Infectious uveitis (if not associated with trauma) is caused by various pathogens: bacteria, 
viruses, fungi, parasitic worms and protozoa (Henderly et al 1987, Nussenblatt et al 1996). 
Toxoplasmic retinochoroiditis is the most common posterior uveitis in many countries. It is 
caused by the intracellular protozoan Toxoplasma gondii, and the vast majority of intraocular 
toxoplasmosis cases are congenital. The diagnosis is commonly made on grounds of the clinical 
picture. Uveitis and different types of retinitis caused by herpes-class viruses are becoming 
more common, together with cytomegalovirus retinitis in immunocompromised patients.  
Non-infectious uveitis is a particularly heterogeneous group of uveitis entities including 
systemic immunological disease-associated chronic uveitis as well as those characterised by a 
specific clinical picture. This group consists of systemic diseases such as HLA B27-associated 
spondyloarthropathies, sarcoidosis and JIA. Specific uveitis entities include e.g. Fuchs 
heterochromic iridocyclitis or Posner-Schlossman syndrome or white-dot syndromes (O'Connor 
1984, Rothova et al 1987, Rosenbaum 1989). 
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Uveitis is designated idiopathic if no causative agent or any association with systemic diseases 
can be identified or if it cannot be categorised as a specific uveitis entity; in 25 to 50% of 
patients uveitis remains undetermined (Schlaegel 1958, Rothova et al 1987, Rosenbaum 1989, 
1990, Rothova et al 1992, Rodriguez et al 1994). 
2.2.3. Occurrence 
The annual incidence of uveitis in Western societies is about 10-20/100 000 and there is little 
variation among figures reported from different countries (Miettinen 1977, Rothova et al 1996, 
Mercanti et al 2001). Recently, the average incidence of uveitis in north-eastern Italy was 
reported to be as low as 11.4/ 100 000 (Mercanti et al 2001). The incidence of uveitis was 
highest among patients in the age group 25 to 44 years. The respective reported prevalences of 
uveitis reported in France and in south-western Finland were 38/100 000 and 23/100 000 
(Vadot et al 1984, Päivönsalo-Hietanen et al 1997).  
According to groups under Rothova and Mercanti, anterior uveitis was the predominant clinical 
type (55% and 58%), followed by panuveitis (20% and 13%), posterior uveitis (17% and 26%) 
and intermediate uveitis (9% and 3%, respectively) (Rothova et al 1992, Mercanti et al 2001).  
Uveitis in children occurs less frequently than in adults, accounting for about 10% of all uveitis 
cases (Miettinen 1977, Pivetti-Pezzi 1996, Rodriguez et al 1996). In a recent Finnish survey 
involving 1122 uveitis patients only 55 (4.9%) were children paralleling an incidence of 4.3/ 
100 000 in south-western Finland (Päivönsalo-Hietanen et al 2000). Most of the children in the 
study in question had anterior uveitis (91%). 
2.2.4. Treatment 
The treatment of uveitis has three main goals: to prevent vision-threatening complications, to 
relieve the patient's complaints and, when feasible, to treat the underlying disease.  
The mainstay of treatment of non-infectious uveitis is local therapy with corticosteroids and 
mydriatics. In refractory cases systemic steroids and other immunosuppressive drugs 
(cyclosporine, methotrexate and azathioprine, sometimes even chlorambucil or 
cyclophosphamide) are used (Nussenblatt et al 1991, Shah et al 1992, Kanski 1999, Jabs et al 
2000). Very recently, Reiff and colleagues reported promising results of tumor necrosis factor α
inhibition-treatment in cases with refractory childhood uveitis (Reiff et al 2001). 
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2.2.5. Complications 
Chronic uveitis can lead to structural damage to ocular tissues. Longstanding intraocular 
inflammation such as seen in JIA can cause an accumulation of calcium at the level of 
Bowman's membrane in the cornea, usually confined to the interpalpebral zone, a condition 
called band keratopathy. The clouded cornea can be cleared by chelating agents or excimer 
laser, but the deposition of calcium tends to recur (Rao et al 1992). 
Cataract develops in uveitic eyes from a number of causes. Severe inflammation in the anterior 
chamber as well as posterior synechiae between iris and lens can result in anterior subcapsular 
lens opacities. Prolonged corticosteroid use is a common reason for posterior subcapsular 
cataract, which may also be associated with inflammation of the posterior chamber. Cataract is 
especially frequent in JIA-associated uveitis, Fuchs heterochromic iridocyclitis and 
intermediate uveitis (Rao et al 1992). Modern ophthalmic surgery has improved the prognosis 
of patients with secondary cataract, but the advisability of implanting an intraocular lens in an 
uveitic eye is still controversial (Foster and Barret 1993, BenEzra and Cohen 2000). 
Secondary glaucoma can develop with any type of chronic inflammation. Blockage of the 
aqueous outflow due to inflammation of the trabecular meshwork and/or peripheral anterior 
synechiae, and pupillary block due to posterior synechia and secondary angle closure are the 
most common causes of elevation of intraocular pressure in uveitic patients. Another important 
cause of ocular hypertension is corticosteroid therapy; 3 to 10% of patients react to topical 
corticosteroids by an elevation of the intraocular pressure generally after 4 to 6 weeks' 
treatment. The reason for this is not known. Patients receiving systemic corticosteroid therapy 
have a lower incidence of elevated intraocular pressure. The degree of pressure rise is probably 
related to the strength and frequency of the medication used. Glaucoma is common in Fuchs 
heterochromic iridocyclitis and JIA-associated uveitis. 
Glaucoma in chronic uveitis is often resistant to medical therapy. Cryo- or laser-surgery of the 
ciliary body or filtration surgery, especially the use of aqueous drainage devices, have improved 
the prognosis of this devastating complication of chronic uveitis (Rao et al 1992, Välimäki et al 
1997).
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Cystoid macular edema (CME) is a major cause of visual impairment in patients with uveitis. 
Loss of foveal reflex and wet, glistening reflex in the foveal area are the first signs of CME, and 
this may progress to the cystoid pattern in a few weeks or months. Treatment of CME must be 
initiated early in view of the potential for permanent visual loss. Most often corticosteroids 
need to be employed (Rao et al 1992). 
Severe uveitis can result in retinal detachment and finally in hypotony and phthisis bulbi. In 
these cases the prognosis is frequently poor, but surgical intervention may be of benefit in some 
cases, whereas retinal surgery in patients with longstanding uveitis is often unsuccessful (Rao et 
al 1992). 
2.2.6. Visual loss
Uveitis is a significant cause of visual impairment. In most epidemiological studies concerning 
the underlying reasons for it, uveitis is seldom taken as a distinct entity. Accordingly, there is 
only little information on the incidence and the prevalence of blindness among the uveitis 
syndromes (Rothova et al 1996, Suttorp-Schulten and Rothova 1996). Based on studies from 
Western Europe and the United States it has been estimated that 5 to 15% of all cases of visual 
loss are caused by uveitis (ten Doesschate 1982, Nussenblatt et al 1996, Rothova et al 1996). 
According to Rothova and associates the most important cause of visual impairment in 
association with uveitis is CME and patients with panuveitis have the worst prognosis. Patients 
with JIA and sarcoidosis had the poorest visual prognosis in their cohort. Toxoplasmosis was 
the most frequent cause of visual loss in unilateral posterior uveitis (Rothova et al 1996).  
2.3. Uveitis in juvenile idiopathic arthritis 
2.3.1. Historical review 
JIA has been recognised since the early 1800's, extra-articular manifestations of JIA being first 
described at the end of that century (Still 1897). However, the occurrence of iridocyclitis in 
patients with JIA was reported more than 10 years later (Ohm 1910). In the 1930's an 
association of arthritis, iridocyclitis, band keratopathy and cataract was noted in two children 
(Friedlander 1933) and later described in six JIA children (Blegvad 1941). It was soon 
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understood that a definite disease subset exists in which both eyes and joints are affected, and 
this was subsequently confirmed in numerous additional reports (Vesterdal and Sury 1950, 
Franceschetti et al 1951, Smiley et al 1957, Ansell and Bywaters 1959, Schaller et al 1969, 
Calabro et al 1970, Schaller et al 1974, Chylack et al 1975, Chylack 1977, Kanski 1977, 
Rosenberg and Oen 1986, Rosenberg 1987).
2.3.2. Occurrence of uveitis in juvenile idiopathic arthritis 
In different series the figures for the occurrence of uveitis vary greatly, as seen in Table 3. The 
frequency of the condition in different subtypes of JIA is discussed more thoroughly at a later 
point.
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Table 3. The occurrence of uveitis in juvenile idiopathic arthritis (JIA) 
Authors Country Year Children with uveitis 
/ all children, n 
Occurrence of uveitis %  
(95% CI) 
Smiley  UK 1965 29/350 8.3 (5.6 to 11.7) 
Laaksonen  Finland 1966 23/411 5.6 (3.6 to 8.3) 
Spalter USA 1975 34/211 16.1 (11.2 to 21.1) 
Chylack et al USA 1975 36/210 17.1 (12.0 to 22.2) 
Cassidy et al USA 1977 38/368 10.3 (7.2 to 13.4) 
Towner et al USA 1983 2/49 4 (0.5 to 14.0) 
Kunnamo et al Finland 1986 6/29 21 (8.0 to 39.7) 
Kanski UK 1988 25/122 20.5 (13.3 to 27.7) 
Andersson Gäre and 
Fasth 
Sweden 1995 11/124 8.9 (4.5 to 15.3) 
Candell Chalom et al  USA 1997 71/760 9.3 (7.4 to 11.6) 
Moe and Rygg Norway 1998 15/109 13.8 (7.3 to 20.2) 
Ylijoki Finland 1998 40/174 23.0 (16.7 to 29.2) 
Variations in the length of follow-up and the thoroughness with which the eyes were examined 
have quite obviously contributed to the discrepant estimates of the occurrence of uveitis. Most 
studies are from special pediatric or ophthalmologic centres and only a minority have been 
population-based (Kanski 1988, Andersson Gäre 1999). The lower frequency of uveitis in early 
reports was evidently partly due to the fact that not all children with JIA had been examined by 
an ophthalmologist (Laaksonen 1966). There may also be real differences between the 
incidences of uveitis detected in the United States and in Europe: e.g. 4 to 17% in the USA, 
compared to 20% in the United Kingdom and 21% and 23% in Finland (Chylack et al 1975, 
Cassidy et al 1977, Towner et al 1983, Kunnamo et al 1986, Kanski 1988, Candell Chalom et al 
1997, Ylijoki 1998). Later studies give lower figures for northern Europe, e.g. 9% and 15% in 
south-western Sweden in two population-based series (Andersson Gäre and Fasth 1995) and 
14% in a study from northern Norway (Moe and Rygg 1998). On the grounds of the above it 
would seem that uveitis in JIA patients may be less frequent in the USA than in most European 
societies.
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2.3.3. Clinical picture of uveitis in juvenile idiopathic arthritis
At the beginning of the last century the eye manifestations of JIA were commonly described as 
the 'ocular triad of Still's disease', comprising iritis, band keratopathy and cataract. Since then, 
numerous cases with JIA and eye lesions have been published, especially in the German 
literature, and it became an established fact that uveitis was more frequent in JIA than among 
the general child population (Blegvad 1941, Vesterdal and Sury 1950, Franceschetti 1951).  
Formerly, the eyes were examined with loupe and ophthalmoscope, and not all patients were 
examined by an ophthalmologist with a slit-lamp microscope (Smiley et al 1957). For this 
reason, perhaps even most of the JIA children with mild asymptomatic uveitis were missed, and 
the more severe cases with band keratopathy and cataracts, frequently leading to visual loss, 
were preferentially diagnosed. 
In any case, it was early understood that uveitis is in most cases insidious at onset and has a 
chronic, sometimes remitting course. In most cases both eyes are affected, either 
simultaneously or within a few months of each other (Kanski 1990, Dana et al 1997). It is 
uncommon that in initially unilateral uveitis the inflammation develops in the other eye more 
than a year from the onset of the process (Steward and Hill 1967, Smiley 1974, Kanski 1990). 
In a majority of cases, uveitis is nongranulomatous, with a faint flare and only a few cells in the 
anterior chamber, by no means easily detectable. Keratic precipitates are from small to medium 
in size, seen mainly in the inferior half of the corneal endothelium. In moderate or severe 
uveitis, cells can be seen in the anterior vitreous and the inflammation may also spread to the 
posterior parts of the eye, sometimes resulting in CME (Kanski 1990).  
AAU with redness and pain tends to occur in older children, and formerly this was regarded as 
a transitory form between silent uveitis in children and the acute recurrent type of iritis of adult 
years (Vesterdal and Sury 1950). AAU is often found in connection with enthesitis-related 
arthritis in children positive for HLA B27, most of whom are boys at the age of 10 or more. 
They may later develop spondyloarthropathy, where AAU is a feature of the disease in up to 
25% of patients in adulthood (Kanski 1990, Andersson Gäre 1999). 
It has been reported that although the activities of joint and eye inflammation may parallel each 
other, they are in fact more commonly independent (Rosenberg and Oen 1986), and a recent 
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study suggests that the presence of uveitis does not influence the long-term articular prognosis 
of oligoarthritis (Cimaz and Fink 1996). However, long-term follow-up studies of this aspect 
are so far lacking. 
2.3.4. Characteristics of uveitis patients in juvenile idiopathic arthritis 
2.3.4.1. Risk of uveitis in subtypes of arthritis 
JIA was early divided according to onset type into three main subtypes: oligoarthritis (early-
onset: <8 years of age, and late-onset: ≥8 years of age), polyarthritis (mostly RF-negative), and 
systemic onset arthritis. The risk of uveitis is greatest in patients with oligoarthritis, 20% and 
about 5% in polyarthritis, while it is rarely detected in systemic-onset JIA (Cassidy 1993, 
Kanski and Petty 1996). Of patients with JIA-associated uveitis, 78 to 91% belong to the 
oligoarthritis group, 7 to 14% have polyarthritis and only 1 to 6% of these children have 
systemic-onset JIA (Kanski 1990, Rao et al 1992). RF-positive patients only seldom develop 
uveitis (Kanski 1990, Kanski and Petty 1996, Dana et al 1997). 
2.3.4.2. Risk of uveitis according to gender 
JIA is more frequent in girls than in boys (sex ratio 3:2), but, independent of this, girls carry a 
higher risk of uveitis than do boys (Kanski 1990, Dana et al 1997). The proportion of girls 
among JIA patients varies from 71 to 97%, and the male/female ratio in JIA patients with 
uveitis is about 1:5 (Ohno et al 1977, Kanski and Shun-Shin 1984, Rosenberg and Oen 1986, 
Wolf et al 1987, Kanski 1989, 1990, Candell Chalom et al 1997). In a recent study, moreover, 
uveitis was found to begin four years earlier in girls than in boys and the duration of active 
disease was longer in girls (Dana et al 1997). Similarly, chronic anterior uveitis in children 
without arthritis is more common in girls; no explanation for this can as yet be given (Perkins 
1966, Ohno et al 1977, Päivönsalo-Hietanen et al 1997). 
2.3.4.3. Onset of uveitis in relation to age of child and onset of arthritis. 
In the majority of children the joint symptoms precede the detection of uveitis and in only 6% 
of cases does uveitis develop first, although higher figures have also been reported (Wolf et al 
1987, Kanski 1990, Dana et al 1997). Uveitis is usually detected during the first seven years of 
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arthritis, but the interval may even be longer than 20 years. Recently, in a large cohort 
consisting of 760 JIA patients in the United States 90% of uveitis cases were found within the 
first 4 years of JIA (Candell Chalom et al 1997). The mean interval from the diagnosis of JIA to 
the onset of uveitis in this series was 21 months. According to Kanski the mean age at diagnosis 
of uveitis is 6 years (range 1 to 35 years) (Kanski 1990), whereas among 43 uveitis children 
with JIA in Boston the mean known age at the onset of uveitis has been found to be as high as 
13 years (Dana et al 1997). If uveitis is diagnosed first, it is often severe, because the diagnosis 
of asymptomatic uveitis is obviously delayed (Kanski 1990). 
In HLA B27-positive boys with late-onset oligoarthritis the possibility of AAU is evident and it 
can precede joint symptoms by months or even years (Giannini et al 1991). 
2.3.4.4. Genetic factors in juvenile idiopathic arthritis with uveitis 
Histocompatibility allele profiles have been studied in uveitis associated with early-onset 
oligoarthritis. In two American series, the HLA allele DRB1*1104 (a split of HLA DR 5) was 
seen to occur significantly more frequently in patients with chronic uveitis compared to those 
not suffering from the disorder (Malagon et al 1992, Melin-Aldana et al 1992). No 
corresponding difference emerged in a patient series collected in Central Europe (Haas et al 
1994). In all three series, the frequency of the allele DRB1*01 was reduced. No data on HLA 
allele distributions in chronic uveitis associated with other forms of JIA have been published, 
probably due to the small number of available cases. The association of ANA with early-onset 
oligoarthritis and uveitis is a known fact, as is the HLA B27 positivity in boys with an older age 
of onset of their arthritis who have AAU and are negative for ANA and RF. 
2.3.5. Treatment of uveitis in juvenile idiopathic arthritis 
The goal of treatment is to cure the uveitis as soon as possible from the very beginning of the 
inflammation in order to save visual acuity and to prevent severe complications of chronic 
uveitis (cataract, glaucoma, CME and band keratopathy). JIA patients with uveitis should be 
referred to an experienced ophthalmologist for treatment and follow-up. Treatment of arthritis 
and uveitis should be undertaken in close co-operation with pediatric rheumatologists familiar 
with the use of immunosuppressive and immunomodulatory medications (Dunn 1996). Further 
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reduction of irreversible visual loss from uveitis is achieved only by early diagnosis and prompt 
treatment of the disorder (Dollfus 1998, Nguyen and Foster 1998). 
2.3.5.1. Local treatment  
The mainstay of treatment in uveitis is local therapy with corticosteroids and mydriatics. Most 
cases can be controlled by topical corticosteroid treatment. Topical use of NSAIDs may be 
added to the regimen (Kanski 1990, Dunn 1996, Dollfus 1998, Nguyen and Foster 1998). 
Periocular corticosteroid injections are sometimes used in refractory cases. Frequently the 
treatment has to be continued for several months, even for years. The frequency of treatment is 
slowly tapered to a level, which keeps the eye inflammation under control. Upon cessation of 
treatment the eyes have to be re-examined within the next few days or weeks to detect possible 
recurrence of uveitis.  
Short-acting mydriatics, e.g. tropicamid or cyclopentolate, are commonly used to prevent the 
formation of posterior synechiae between iris and lens. Long-acting mydriatic drops such as 
atropine may cause adhesions in the chamber angle and are recommended only in severe cases. 
Constant mydriasis may impair the development of normal central visual acuity and result in a 
form of vision deprivation called amblyopia (Kanski 1990) 
2.3.5.2. Systemic treatment 
If uveitis is severe or prolonged, systemic steroids are frequently used, at onset with larger 
doses and subsequently tapering to as low a level as necessary to stabilise the situation. Most 
JIA patients have NSAIDs in their treatment, usually naproxen. In about 30% of patients with 
JIA-associated uveitis the inflammation cannot be controlled by anti-inflammatory agents only, 
and initiation of low-dose, once-a-week methotrexate therapy is recommended. The dosage of 
methotrexate can be increased even to 17.5-20.0 mg per week to control the uveitis. There is 
some evidence that this drug has both anti-inflammatory and immunosuppressive effects, while 
folic acid can prevent adverse effects (Nguyen and Foster 1998). If methotrexate is not well 
tolerated or is ineffective, other immunomodulatory drugs can replace it or be used in 
combination with it: azathioprine, low-dose cyclosporine, or even chlorambucil or 
cyclophosphamide (Hemady et al 1992, Schlote et al 1996, Vitale et al 1996, Savolainen et al 
1997, Weiss et al 1998, Savolainen 1999). In some refractory chronic uveitis patients, treatment 
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with intravenous immunoglobulin has been tried, but there is no documentation of its effect in 
childhood uveitis (Rosenbaum et al 1999). 
2.3.6. Screening for uveitis in juvenile idiopathic arthritis 
Ophthalmologic examination of patients with JIA was highly recommended as far back as 1957 
(Smiley et al 1957). Subsequently Kanski published several papers on JIA-associated uveitis 
and his screening program is widely accepted. It is presented in Table 4 (Kanski 1989). 
Table 4.  Screening program for uveitis in juvenile idiopathic arthritis 
Onset type of JIA Risk of uveitis Interval between eye examinations 
Systemic (+) 12 months 
Polyarticular + 6 months 
Polyarticular, ANA-positive ++ 6 months 
Pauciarticular +++ 3-4 months 
Pauciarticular, ANA-positive ++++ 2-3 months 
It is reasonable to monitor all JIA patients for at least seven years from the onset of arthritis. 
Uveitis will commonly appear within 12 months, and in 90% of cases during the first 4 to 5 
years of arthritis (Kanski 1990, Dollfus 1998). Similar guidelines for ophthalmologic 
examinations in children with JIA have also been recommended elsewhere (Yancey et al 1993, 
Boone et al 1998). 
2.3.7. Prognosis of uveitis in juvenile idiopathic arthritis 
The prognosis of JIA-associated uveitis has continuously improved (Sherry et al 1991, Cabral et 
al 1994, Dana et al 1997). In the first reports on uveitis in JIA the complication rate was very 
high, partly owing to a delay in the diagnosis of uveitis. It was commonly thought that most 
patients with band keratopathy would eventually become blind. In 1957 Smiley and colleagues 
reported that 10 out of 183 children with JIA had uveitis, and band keratopathy was found in 
five of them, cataract in three and secondary glaucoma in one child. Visual acuity was 
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preserved normal in five cases and uveitis was ongoing in five. One child was referred because 
of longstanding uveitis: cataract and blindness were recorded 2.5 years before the onset of 
arthritis (Smiley et al 1957). In the study of 51 JIA patients by Wolf and associates, 22% of 89 
eyes with uveitis had visual loss to 20/200 or worse, and complications were common: cataract 
in 46%, band keratopathy in 30%, and glaucoma in 27% of the eyes. The degree of 
inflammation found on initial ocular examination correlated with the severity of visual loss and 
complications (Wolf et al 1987). 
According to Kanski, 25% of JIA patients with uveitis have a good prognosis: patients either do 
not need medication or do well with only topical corticosteroids. Half of his 103 patients had 
moderate to severe uveitis with good response to treatment, but needed long-term therapy. A 
poor prognosis with complicating cataract and glaucoma was found in 25% of children (Kanski 
1988).
A report published a decade ago compared the severity of chronic uveitis in children with 
juvenile oligoarthritis in Seattle in 1975 and in 1989. The prevalence of eye diseases declined 
from 45% to 13% and the proportion of patients with severe visual loss diminished from 21% to 
zero (Sherry et al 1991). More effective treatment and early detection of uveitis obviously 
played some role, but there may also have been differences in the selection of patients.  
Cabral and associates summarised the prognostic data from previous studies and concluded that 
the risk of developing uveitis five years after the onset of JIA was small (Cabral et al 1994). 
The complication rate in their own series was 31%. On the other hand, normal vision was saved 
in the majority of their patients with JIA/juvenile psoriatic arthritis and uveitis. 
One recent study of JIA-associated uveitis has evaluated visual outcome prognosticators 
retrospectively in a series of 43 patients (Dana et al 1997). Uveitis was chronic in 93%, and 
97% had iridocyclitis. Cataract surgery was performed in 44% of cases, and 37% underwent 
vitrectomy. Male sex, shorter duration of uveitis, older age at disease onset, and a shorter delay 
in presentation to an experienced ophthalmologist were associated with improvement in visual 
acuity. 
In a Finnish prospective 15-year follow-up of 174 children with JIA, four (2%) had decreased 
visual acuity (<20/70); two of them had had uveitis, the other two cataract (Ylijoki 1998).  
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Better prognosis of uveitis may be a consequence of routine screening of JIA patients for its 
detection and advances in the medical and surgical treatment of both arthritis and uveitis (Dana 
et al 1997). As shown in the above-mentioned studies, the complication rate today is lower than 
earlier and the visual prognosis has improved. The frequency of band keratopathy has 
diminished, and due to modern surgical techniques it is possible to restore good visual acuity 
after cataract and glaucoma operations. Formerly secondary glaucoma due to chronic uveitis 
was an important cause of visual loss, its response to medical treatment often being poor. 
However, the known complications of prolonged use of corticosteroids: ocular hypertension 
and posterior capsular cataract, are frequently seen in patients with chronic uveitis, and in some 
patients the development of CME causes permanent visual impairment despite vigorous 
treatment of uveitis (Nguyen and Foster 1998). 
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3. AIMS OF THE PRESENT STUDY 
The impulse to undertake the present thesis came from observations made in the context of 
practical work with patients suffering JIA-associated uveitis (I). It became clear that systematic 
efforts to increase knowledge of the occurrence, characteristics and prognosis of this condition 
improves its treatment and the prognosis of patients. 
There are only few population-based studies providing information on the occurrence of uveitis 
in patients with JIA, and none of these has dealt specifically with eye problems. A population-
based patient series had already been collected in Finland (Kaipiainen-Seppänen and 
Savolainen 1996) and the patients were now evaluated from the ophthalmological point of view 
(II). 
A number of studies have dealt with the HLA associations of JIA-associated uveitis. There are, 
however, very few sibling series on JIA and no special attention has been paid in these to 
uveitis. One sibling series had been collected at the Rheumatism Foundation Hospital in 
Heinola (Savolainen et al 2000) and the occurrence and characteristics of uveitis in these sibling 
pairs is described in study III. 
The majority of studies on JIA-associated uveitis are retrospective and come from special 
ophthalmologic or pediatric centres. A prospective study of the occurrence and characteristics 
of uveitis among patients with recently diagnosed JIA at the Rheumatism Foundation Hospital 
was carried out in close co-operation with an ophthalmologist and pediatric rheumatologists 
(IV). 
It is commonly believed that arthritis in JIA patients is usually mild and has a good prognosis, 
but there is very little solid evidence substantiating this view. The activity of arthritis in RF-
negative JIA patients with oligoarthritis or polyarthritis in study IV was compared between 
cases with and without uveitis (V). 
There is very little information available on the relative importance of different arthritides and 
comparable conditions as a cause of visual loss. The Finnish Register of Visual Impairment 
provided a basis to approach this issue and a study was carried out along these lines (VI).
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4. PATIENTS AND METHODS 
4.1. Utilization of the Finnish registers 
The Finnish health care system is mainly public. In addition to the nation-wide sickness 
insurance scheme, several other population-based registers exist, e.g. The Finnish Register of 
Visually Impaired. These sources provide a good basis for epidemiological studies. 
4.1.1. The Finnish sickness insurance scheme 
Since 1966 The Finnish Sickness Insurance Act has provided for the prescription of drugs free 
of charge for certain chronic conditions, including chronic inflammatory rheumatic diseases. 
Following a number of amendments, only 75% of costs are nowadays reimbursed. The Finnish 
national sickness insurance scheme covers the entire population. Eligibility requires a 
comprehensive medical certificate written by the attending physician and approved by an expert 
adviser on behalf of the sickness insurance scheme. 
The epidemiological section of this thesis (II) involved the 114 JIA children (the term JRA was 
used in the original communication), in whom the diagnosis had been made in 1980, 1985 and 
1990 in the districts of five of the 21 central hospitals in Finland (Keski-Suomi, Tampere, 
Päijät-Häme, Kymenlaakso, Kuopio) (Kaipiainen-Seppänen and Savolainen 1996). 
The study area (Figure 1) covered about 1 300 000 inhabitants, i.e. one-fourth of the population 
of Finland, including a population base of about 270 000 children under 16 years. The patients 
in this study were entitled to specially reimbursed medication for JIA. A patient was defined as 
an incident case if his/her age at the time of diagnosis was under 16 years and if he/she met the 
ARA criteria (Brewer et al 1977). 
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Figure 1. The study area of the population-based JIA series 
In this retrospective study the clinical data on the course of arthritis and associated uveitis were 
collected from drug reimbursement certificates and hospital records covering the period up to 
autumn 1997. The occurrence and characteristics of uveitis were determined.
4.1.2. The Finnish Register of Visual Impairment 
The Finnish Register of Visual Impairment was founded in 1983. Its function is regulated by 
law and it is technically maintained by the Finnish Federation of Visually Impaired under the 
supervision of a governmental office (National Research and Development Centre for Welfare 
and Health). Specialists in ophthalmology (about 420 in a population of 5.1 million at the end 
of 1997) and the ophthalmologic hospital units are obliged to give notification of patients in 
whom the corrected visual acuity is permanently less than 20/60 in the better eye or if the 
patient for some other reason (e.g. visual field defects) is regarded as comparable in respect of 
the above visual impairment. The notification form provides information on the patient's 
personal details, diagnoses and severity of visual impairment (visual acuity and visual field). 
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This register provided a basis for a study of the importance of different uveitis entities as a 
cause of visual handicap (VI); special emphasis was paid to arthritides and comparable 
conditions. The coverage of the register is not complete, but during the last few years the 
proportion of different diagnostic categories and the age distribution of cases have been quite 
stable. At the end of 1996, the register covered 11 022 living persons, including 296 subjects 
(2.9%) diagnosed as having uveitis. The most common causes of visual impairment in 1996 
were senile macular degeneration 35%, hereditary retinal degeneration and diabetic retinopathy 
10% each, glaucoma and other diseases of the optic pathway 9%, and congenital developmental 
defects 6%. 
On the basis of the Finnish Register of Visual Impairment a total of 296 uveitis patients were 
found and data concerning these patients were collected from hospital records. The information 
obtained was frequently incomplete on patients blinded a long time ago. For this reason only 
those 174 patients who had been handicapped during 1980-1996 were included in the present 
study. The demographics of the patients, the clinical course of uveitis, and possible associations 
with systemic diseases were evaluated (VI). 
4.2. Patients with juvenile idiopathic arthritis from the Rheumatism Foundation 
       Hospital 
Finland is divided into five university hospital regions, each covering about one million 
inhabitants, and further into 21 central hospital districts. Patients come to central hospitals from 
primary care, i.e. from health centres, which are responsible for health care and health check-
ups of residents in their districts. Patients are required to attend their own local health facilities 
except in emergencies. In addition to this tax-financed system there are private physicians who 
can refer patients to hospitals of all levels. Very few private clinics exist in Finland; some of 
these are also partially financed from public resources. 
The Rheumatism Foundation Hospital is a semi-private clinic, which receives patients from 
university hospitals and other central hospitals, and directly from primary care, especially if 
patients live in the region surrounding the Hospital. The Hospital provides in- and outpatient 
care in conservative rheumatology, orthopedics and rehabilitation for adults and children. Of 
JIA patients only the mildest cases remain in the care of central hospitals, others being referred 
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further to university clinics or to the Rheumatism Foundation Hospital. It has been estimated, 
on the basis of an incidence study in Finland (Kaipiainen-Seppänen and Savolainen 1996) and 
the patient register of the Rheumatism Foundation Hospital, that about two-thirds of JIA 
patients are seen at the Hospital at some time, in many cases once or twice, while severe cases 
are constantly monitored there (II).  
A series of siblings affected with JIA was collected at the Rheumatism Foundation Hospital 
over a period of 15 years. Patients (when appropriate) and their parents were systemically asked 
about their family history of rheumatic diseases. Altogether 37 families with two or three 
affected siblings were identified; there were 80 children (49 sib pairs) with a diagnosis of JIA 
according to the Durban criteria (Petty and Southwood 1998). The total number of JIA patients 
among whom the familial cases were found was estimated to be 2000 (Savolainen et al 2000). 
Except for five patients, all the siblings had been treated at the Rheumatism Foundation 
Hospital. All were examined by an ophthalmologist at the Hospital or at central hospitals 2 to 4 
times a year for detection of insidious uveitis. The occurrence and characteristics of uveitis 
were assessed in this series (III). 
At the Rheumatism Foundation Hospital a total of 426 children with recently diagnosed JIA 
during the period 1989-1996 were sent for ophthalmologic examination for possible insidious 
uveitis. The occurrence and characteristics of uveitis were assessed prospectively in this patient 
series. During the follow-up an ophthalmologic examination was carried out 2 to 4 times a year, 
more often in cases with uveitis (IV). 
In the above patient series uveitis was found in 104 out of 426 cases with JIA. The activity of 
arthritis in JIA patients with RF-negative oligoarthritis or polyarthritis without uveitis (276 
patients) and with it (96 patients) were compared (V). Remission of JIA was stated recorded, if 
no tender or inflamed joints were found and the patients' erythrocyte sedimentation rate (ESR, 
<10mm/h) and/or C-reactive protein (CRP, <10mg/l) were normal. Additionally, patients had 
had no medication or other treatment for arthritis during the last six months (remission without 
drugs). 
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4.2.1. Diagnosis of juvenile idiopathic arthritis and follow-up of patients 
Pediatric rheumatologists confirmed the diagnosis of JIA in all patients according to approved 
main criteria (Brewer et al 1977, Wood 1978, Petty and Southwood 1998). The subtype of 
arthritis was defined after six months' duration of JIA. The characteristics and course of the 
disease were evaluated during the follow-up. ANA and RF were determined in almost all cases, 
HLA B27 less frequently. The clinical status of patients with active JIA was followed by 
pediatricians after regular intervals, usually 2 to 6 times a year.  
4.2.2. Ophthalmologic examination, treatment and follow-up of uveitis 
All patients with suspected or diagnosed JIA were sent for ophthalmologic examination to 
detect insidious uveitis as soon as possible after the onset of arthritis, and 2 to 4 times yearly 
thereafter. The examination included determination of the best corrected visual acuity, careful 
biomicroscopy of the anterior segment of the eye and evaluation of cells and aqueous flare. 
After dilatation of the pupil (by tropicamide or/and cyclopentolate and phenylephrin when 
needed) examination of the anterior vitreous body was performed under slit lamp and the 
fundus of the eye was studied with a 90 dioptre lens. Ocular pressure was measured when 
feasible. Uveitis was classified according to the recommendations of the IUSG (Bloch-Michell 
and Nussenblatt 1987). Grading of anterior chamber flare and cells was done with modification 
of the recommendations of Rao and Foster (1992) and Nussenblatt and group (1996). The data 
are presented in Table 5. 
Table 5.  Grading of anterior chamber flare and cells in uveitis in JIA  
Anterior chamber flare (wide beam and narrow slit) Anterior chamber cells per field
Grade Description Grade Description 
0 None 0 None 
1+ Faint flare (barely detectable) 1+ 3-10 cells 
2+ Moderate flare (iris and lens clearly seen) 2+ 10-20 cells 
3+ Marked flare (iris and lens hazy) 3+ 20-50 cells 
4+ Intense flare (coagulated aqueous humour with fibrin) 4+ 50+ cells 
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Because the majority of our patients were young and biomicroscopic examination was 
sometimes technically difficult, wide beam and narrow slit were commonly used (IV and V). 
The patient was assessed as having anterior uveitis when three or more cells in the anterior 
chamber and/or precipitates on the endothelium were found in biomicroscopy. Aqueous flare 
alone was not taken as a sign of active inflammation. Inflammation in the vitreous body was 
evaluated according to the recommendations of Nussenblatt and colleagues (1996). The 
characteristics and course of uveitis were recorded and complications (cataract, glaucoma, 
CME and band keratopathy) were carefully registered. CME was evaluated clinically 
(fluorescein angiography was not available) (Rao et al 1992, Nussenblatt et al 1996). Treatment 
of uveitis was initiated promptly after the diagnosis by local therapy, which was reinforced in 
refractory cases with systemic therapy in close co-operation with pediatric rheumatologists (IV, 
V) or rheumatologists (I). 
4.3. Statistical methods 
The results in the studies discussed here are expressed as mean, standard deviation (SD), range, 
and 95 per cent confidence intervals (95% CI). Statistical significance was evaluated by T-test, 
Fisher's exact test, Mann-Whitney test and Chi-square test (II - V). The normality of variables 
was evaluated by Kolmogorov-Smirnov statistics, with Lilliefors significance or Shapiro-Wilk 
statistics (II-VI). Kaplan-Meier curves were used to illustrate information on the cumulative 
proportions of uveitis and the difference between groups tested by Log-rank test (IV). 
Prognostic factors predicting uveitis were analysed using univariate and multivariate 
proportional hazard regression models (Cox's regression models) (IV). 
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5. RESULTS 
5.1. Occurrence of uveitis in juvenile idiopathic arthritis (I, II, III, IV) 
5.1.1. Late-onset uveitis in juvenile-type chronic polyarthritis - a case report (I) 
A female with seronegative polyarthritis since early adulthood developed silent chronic uveitis 
15 years after the onset of arthritis. The polyarthritis was diagnosed after the 16th birthday, but 
re-examination of the patient records revealed an erosive finger joint visible in X-rays at the age 
of 14. The patient was ANA-positive and carried the HLA B27 antigen. Arthritis was refractory 
to conventional anti-rheumatic medication and severe uveitis did not respond to either topical 
corticosteroid treatment or oral corticosteroid plus cyclosporine. Finally, combination therapy 
with oral corticosteroids, cyclosporin A and methotrexate calmed down the sight-threatening 
uveitis and aggressive polyarthritis within two months. The collaboration of ophthalmologist 
and rheumatologists was important in treating this patient in respect of determining the optimal 
management. 
5.1.2. Population-based occurrence of uveitis in juvenile idiopathic arthritis (II)
Uveitis was found in 18 out of the 114 JIA patients (16%). A total of 70% of these 114 were 
female, in 75% the onset type of JIA was oligoarticular and 43% of the patients were ANA-
positive. Only four cases were RF-positive, while systemic onset JIA was diagnosed in seven. 
The mean age at the diagnosis of JIA was 7.4 years (range 0.8-15.8 years). HLA B27 was 
positive in 24 out of 66 HLA-typed patients. The mean follow-up period was 7.5 years (range 
0.5-17 years).  
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Table 6. Main characteristics of 18 juvenile idiopathic arthritis patients with uveitis 
in a population based-group of 114 children. 
Type of uveitis Characteristic 
Chronic Healed 
chronic
Episodic Acute with 
symptoms 
Male/Female, n 3/3 1/2 0/7 2/0 
Oligoarthritis/polyarthritis cases at 
onset of arthritis, n 
4/2 2/1 5/2 2/0 
Age at onset of arthritis, mean 
(range), yrs 
5.2
(1.5 to 15.8) 
5.0
(4.0 to 5.9) 
7.1
(1.6 to 14.3) 
13.4
(13.1 to 13.6) 
#Interval to uveitis, mean (range), 
yrs 
1.7
(0 to 8.2) 
3.4
(0 to 5.6) 
4.7
(0 to 11.7) 
-0.5
(-0.6 to -0.4) 
Uni-/bilateral uveitis cases, n 2/4 0/3 6/1 2/0 
ANA-positive/negative children, n 3/3 2/1 4/2* 0/2 
HLA B27-positive/negative 
children§, n 
1/2 0/3 2/0 2/0 
*One patient not tested; §eight patients not tested  
#Interval from arthritis to uveitis denotes interval between the onset of arthritis and the onset of 
uveitis; a negative value implies that uveitis was detected prior to arthritis. 
As seen in Table 6, uveitis was found in 18 patients (16%). The male/female ratio was 1:2; 13 
children had oligoarthritis (mean age 5.7 years at the diagnosis of JIA) and five had 
polyarthritis (mean age 9.7 years at the diagnosis of JIA). The diagnosis of JIA was made at a 
mean age of 6.8 years (range 1.3-15.8 years) in the case of those 18 with uveitis. The uveitis 
diagnosis was made at a mean age of 9.7 years (8.8 years in oligoarthritis). The onset of uveitis 
was asymptomatic in most patients (15/18) and bilateral in eight; only two HLA B27-positive 
boys with late-onset oligoarthritis had acute symptomatic uveitis of short duration, and one girl 
had marginal corneal ulceration and mild uveitis at the onset of her RF-positive polyarthritis. 
In six patients uveitis ran a chronic course and led to complications (cataract, glaucoma or 
CME) in three cases; in all these patients uveitis had preceded the onset of arthritis. The overall 
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visual prognosis was nonetheless good; in only one patient did visual acuity in one eye remain 
as low as 20/400. 
5.1.3. Occurrence of uveitis in sibling pairs with juvenile idiopathic arthritis (III) 
A total of 80 JIA children belonging to 37 families with two or three affected siblings (49 sib 
pairs) were found at the Rheumatism Foundation Hospital during 15 years. Uveitis was 
diagnosed in 21 of the patients (26%). Three pairs were concordant for the presence of uveitis. 
The expected number was 3.4.  
In this series of JIA patients with uveitis both genders were similarly affected. Oligoarthritis 
was the most frequent type of JIA, and ANA positivity was common. Patients with uveitis were 
somewhat younger at the onset of JIA than those without. Patients with uveitis tended to be 
more frequently positive for HLA B27 compared to those without; all siblings concordant for 
uveitis carried this allele. 
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Table 7.  Main characteristics of the 21 JIA patients with uveitis in the sibling study  
Type of uveitis  Sex Onset 
type of 
JIA 
Course
type of 
JIA 
Age at 
diagnosis 
of JIA, 
yrs 
Interval 
to
uveitis*, 
yrs 
Eye 
afflicted 
ANA HLA 
B27 
Three sibling pairs, 
concordant for uveitis: 
        
   healed chronic F oligo oligo 6.0 0.2 left + + 
   chronic F oligo oligo 2.3 3.1 left - + 
   healed chronic M oligo oligo 2.8 5.0 both - + 
   chronic F oligo oligo 4.0 1.3 left + + 
   healed chronic F oligo oligo 1.3 0.2 both + + 
   chronic M oligo oligo 2.7 0.0 both + + 
Fifteen single cases, 
discordant for uveitis: 
        
   chronic M poly poly 1.3 3.5 both + - 
 M oligo oligo 1.0 3.1 both - - 
 F oligo oligo 6.8 -0.5 both - + 
 M oligo oligo 1.8 2.6 right + + 
 F oligo poly 1.7 0.0 both + - 
 F poly poly 1.9 0.3 both + - 
 F oligo oligo 3.4 0.6 left + - 
 M poly poly 4.8 0.1 both + - 
 F oligo oligo 2.1 3.1 both - - 
 M oligo oligo 6.8 0.0 both + - 
   healed chronic M poly poly 4.3 -0.2 left - + 
 M oligo oligo 3.4 3.2 both + - 
 F poly poly 3.3 1.9 both + - 
   acute M enthesitis
- related 
enthesitis
- related 
13.3 -0.8 left - + 
 M enthesitis
- related 
enthesitis
- related 
11.3 -0.8 right + + 
*Interval to uveitis denotes the interval between the onset of arthritis and the appearance of uveitis; a 
negative value indicates that the uveitis was detected previous to diagnosis of arthritis. 
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Acute symptomatic anterior uveitis was diagnosed in two boys with oligoarthritis, who later 
developed enthesitis-related arthritis. The remaining 19 out of 21 siblings with uveitis had the 
insidious anterior form. In five cases uveitis was diagnosed before (two patients) or at diagnosis 
(three patients) of JIA. Two children had uveitis of short duration (<3 months) and in 13 cases 
uveitis persisted at the end of follow-up. Uveitis was bilateral in almost two-thirds of the 
patients and complicating cataract was detected in eight, secondary glaucoma in one and CME 
in one. However, the final visual acuity was good (>20/40) in all patients except the one with 
glaucoma; the right eye had visual impairment to perception of light. 
5.1.4. Occurrence of uveitis in recently diagnosed juvenile idiopathic arthritis (IV)  
In a large cohort of 426 patients with a recent diagnosis of JIA uveitis was detected in 104 cases 
(24%) (The designation JCA was used in the original paper according to EULAR criteria). The 
demographic and disease-related characteristics of these patients are described in Table 8. 
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Table 8. Main demographic and disease-related characteristics of JIA patients according to 
the presentation of uveitis. 
Characteristics JIA with uveitis 
n=104
JIA without uveitis 
n=322
P
Male / Female, n (%) 35 (34) / 69 (66) 115 (36) / 207 (64) 0.80 
Age at diagnosis of JIA, mean (range) 4.8 (0.6-15) 7.3 (0.9-16) <0.001 
Age at diagnosis of uveitis, mean (range) 5.9 (1.1-17.7)   
Interval from JIA to uveitis, mean (range) 1.1 (-2.4-6.5)   
Antinuclear antibody positive, n (%) 69 (66) 119 (37) <0.001 
HLA B27 antigen-positive, n (%)* 20/74 (27) 69/202 (31) 0.50 
Oligoarticular disease type, n (%) 76 (73) 207 (64) 0.12 
Polyarticular disease type 
     Rheumatoid factor-negative, n (%) 
     Rheumatoid factor-positive, n (%) 
25 (24) 
1 (1) 
77 (24) 
16 (5) 
1.0
0.105
Systemic disease type, n (%) 1 (1) 16 (5) 0.105 
Other types of JIA, n (%) 1 (1)§ 6 (2)# 0.917 
*HLA B27 was not examined in all cases; §one patient with psoriatic arthritis; #one patient with 
ulcerous colitis, one with psoriatic arthritis, one with reactive arthritis, and three with 
spondyloarthropathy
The patients were collected during the years 1989-1996 at the Rheumatism Foundation Hospital 
and the mean prospective follow-up was 4.5 years for all patients and 5.8 years for those with 
uveitis. In this series uveitis was detected early on in the course of JIA, a mean 1.1 years from 
the diagnosis of JIA, the median as short as 0.3 years. The age at the diagnosis of JIA was 
significantly lower in patients with uveitis than without it and ANA positivity was more 
frequent among uveitis patients (P<0.001). 
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Proportionally, uveitis was as common among girls as among boys, as well as in patients with 
oligoarthritis and with RF-negative polyarthritis. 
Uveitis was asymptomatic in 99 out of 104 children, including: chronic anterior uveitis in 80, 
recurrent episodes of uveitis in seven, and uveitis of short duration (<6 months) in 12 patients. 
Acute anterior uveitis of 4 to 6 weeks' duration was diagnosed in five cases: one HLA B27-
negative girl and four HLA B27-positive boys. Uveitis was bilateral in 63% of patients and still 
active in 61% at the end of follow-up. 
Complications of uveitis were detected in 24% of cases; of these cataract was the most 
common. A cataract operation was undertaken in nine cases, in six of them with intraocular lens 
implantation. The postoperative activity of uveitis was not influenced by the surgical method 
used (with intraocular lens or without). Secondary glaucoma was refractory to conservative 
treatment in three patients, who underwent a filtering operation with an implant in two of them.  
Of all patients with JIA 12% and of uveitis patients 49% developed uveitis before arthritis or 
within three months from the onset of joint symptoms. In 91% of JIA-associated uveitis cases 
uveitis appeared within the first four years after the onset of JIA. The visual prognosis was 
good: in three children visual acuity decreased to 20/60 or less; none became blind. 
Proportional hazard models were used to characterise the determinants of uveitis in those 
patients with oligoarthritis or polyarthritis among whom uveitis had developed only after the 
diagnosis of JIA. The only significant determinants of uveitis in this specific group were ANA 
positivity and early onset of arthritis. 
The three different groups of children with uveitis are compared in Table 9. 
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Table 9.  Comparison of uveitis patients in the three different study populations above  
Characteristic Epidemiological 
study 
n=114
Sibling 
series
n=80
Clinic-based 
series
n=426
Female, % 70 61 65 
Oligoarthritis, % 75 69 66 
ANA-positive, %* 43 (49/113) 56 44 
HLA B27-positive, %* 36 (24/66) 36 31 (86/276) 
RF-positive, %* 4 (4/112) 0 4 
Uveitis patients, % 16 26 24 
Visual loss <20/60 in eyes with uveitis, % 3 2 4 
Complications of uveitis,  
    eyes (patients), % 19 (22) 38 (38) 22 (24) 
Age at diagnosis of arthritis, mean (range), 
yrs 
7.4
(1.3 to 14.3) 
4.7
(1.0 to 13.3) 
6.7
(0.6 to 16.0) 
Age of uveitis patients, mean,     
    at diagnosis of arthritis, yrs 
    at diagnosis of uveitis, yrs 
6.8
9.7
4.1
5.4
4.8
5.9
Follow-up, mean, yrs 7.5 6.5 4.5 
*number tested in parenthesis 
In the two hospital-based series uveitis occurred more often and the children were younger at 
the onset of arthritis than in the population-based study. Complications of uveitis were more 
common in the children in the sibling series with uveitis, but visual loss was equal in all three 
groups.
5.2. Uveitis as a marker of active arthritis in 372 patients with juvenile idiopathic 
       seronegative oligoarthritis or polyarthritis (V)  
A comparison of the activity of arthritis was made between JIA patients with uveitis and 
without it in the hospital-based cohort of 426 children with recently diagnosed JIA during a 
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mean follow-up of 4.5 years. To enhance the homogeneity of the study series, only patients 
with rheumatoid factor- negative juvenile oligoarthritis or polyarthritis were included. As a 
result, the study group comprised 372 children with JIA, of whom 96 had insidious uveitis. The 
basic data on the patients are presented in Table 10. 
Table 10. Basic demographic and clinical data on 372 JIA patients grouped according to the 
occurrence of uveitis. 
 Patients with 
uveitis 
Patients without 
uveitis 
p Value 
 n=96 n=276  
Boys : Girls, n (%) 30 (31) : 66 (69) 97 (35) : 179 (65) 0.49 
Age at the diagnosis of arthritis#, years 4.4 (3.5) 7.1 (4.4) <0.001 
Age at the diagnosis of uveitis#, years 5.6 (3.4)   
Onset type of arthritis, n (%) 
      oligoarthritis : polyarthritis  71 (74) : 25 (26) 202 (73) : 74 (27) 0.88
Extended type of oligoarthritis§ , n (%) 13 (18) 23 (11) 0.21 
ANA-positive patients, n (%) 67 (70) 110 (40) <0.001 
HLA B27-positive patients, n 16 (67 tested) 60 (184 tested) 0.18 
ESR#, mm/h
      at the diagnosis of arthritis 
      at the end of follow-up 
36 (25) 
14 (12) 
28 (24) 
11 (9) 
0.001
0.02
Hemoglobin#, g/l  
      at the diagnosis of arthritis 
      at the end of follow-up 
118 (11) 
127 (10) 
121 (12) 
129 (11) 
0.008
0.114
Patients treated with, n (%) 
      oral prednisolone 
      methotrexate 
      glucocorticoid joint injections 
48 (50) 
56 (58) 
90 (94) 
69 (25) 
113 (41) 
188 (68) 
<0.001
0.003
<0.001
Patients with remission of arthritis, n (%) 20 (21) 116 (42) <0.001 
Follow-up time#, yrs  5.7 (2.2) 4.1 (2.2) <0.001 
#mean (standard deviation); §oligoarthritis extended to polyarthritis during the course of arthritis
52
Laboratory parameters (hemoglobin, ESR), need of systemic and local corticosteroid therapy 
and use of methotrexate reflected significantly greater inflammatory joint activity in JIA 
patients with uveitis than without it. The number of inflamed joints was significantly greater at 
the end of the follow-up in patients with persistent polyarthritis and uveitis compared to those 
polyarthritis patients without uveitis. 
5.3. Uveitis as a cause of visual loss in arthritides and comparable conditions (VI) 
At the end of 1996 the Finnish Register of Visual Impairment included 174 patients (72 male, 
102 female) handicapped after 1980, in whom uveitis was the main cause of visual impairment. 
An inflammatory rheumatic disease or comparable condition had been detected in 22% of them. 
Uveitis in this study resulted in visual loss within an average of 18 years, and visual acuity 
remained <20/60 in 133 patients (in 41 cases central visual acuity >20/60 after effective 
medical and surgical treatment of uveitis).  
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Table 11.  Age at onset of etiologic disease or comparable condition and at diagnosis of uveitis, 
                      and years up to handicapping from the onset of uveitis 
Etiologic disease Patients, 
n
Age at diagnosis 
of etiologic 
disease, yrs 
Age at diagnosis 
of uveitis, yrs 
Years up to 
handicapping 
  Mean Range Mean Range Mean Range 
JIA 14 9 1 to 30 11 3 to 30 11 1 to 41 
AS 7 36 15 to 60 32 22 to 46 22 12 to 34 
ReA 3 42 29 to 60 48 29 to 65 6 0 to 16 
RF-negative arthritis 4 22 15 to 24 29 17 to 52 19 5 to 47 
SLE 1 8  9  0  
PAN 1 59  27  37  
PM 1 24  24  9  
Beçhet's disease 2 27 22 to 31 27 23 to 31 2 1 to 2 
Sarcoidosis 5 53 26 to 87 43 13 to 82 17 0 to 55 
Toxoplasma choroiditis 10 NA  19 0 to 71 31 0 to 70 
Tuberculous choroiditis 8 NA  23 10 to 34 37 14 to 60 
Miscellaneous other 
diseases 
20 NA  37 1 to 78 15 0 to 55 
Back pain/arthralgia 15 43 14 to 68 49 5 to 68 7* -3 to 26 
Trauma/surgery 9 NA  46 2 to 92 14* -1 to46 
No established etiology 74 NA  40 0 to78 19* -7 to 66 
All patients 174 NA  36 0 to 92 18* -7 to 70 
* Negative years mean that visual impairment was in some cases detected before diagnosis of 
uveitis. Abbreviations: AS, ankylosing spondylitis; ReA, reactive arthritis; SLE, systemic lupus 
erythematosus; PAN, polyarteritis nodosa; PM, polymyalgia rheumatica; NA, not available. 
As seen in Table 11, JIA was the largest single group of inflammatory rheumatic diseases, 
causing uveitis in 14 out of 174 (8%) patients. In 8 (57%) cases of JIA visual acuity remained 
permanently impaired <20/60. 
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Ankylosing spondylitis and reactive arthritis had been diagnosed in seven and three patients, 
respectively. Visual loss occurred in a markedly shorter time in the latter than in the former 
disease group (6 versus 22 years). In the four RF-negative RA cases found visual impairment 
developed within a mean 19 years from the diagnosis of uveitis. One young girl fell ill with 
systemic lupus erythematosus at the age of eight and was rapidly blinded with complicating 
herpes zoster uveitis. Uveitis with Beçhet's disease in two young men caused severe visual loss 
within months. Sarcoidosis was associated with uveitis in five patients and polyarteritis nodosa 
and polymyositis in one each. An additional 15 patients had back pain/arthralgia but in none of 
them could an inflammatory rheumatic disease be established. In 74 of 174 (43%) patients the 
etiology of uveitis remained unknown. 
Uveitis resulted in visual impairment after a mean of 18 years and in 22% of patients an 
associated inflammatory rheumatic disease or comparable condition could be identified. 
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6. DISCUSSION 
6.1. Discussion of patients and methods  
6.1.1. Genetic background of the Finnish population 
Although the majority of Europeans speak Indo-European languages, about 24 million speak 
Finno-Ugric languages such as Hungarian, Finnish, and Estonian. Based originally on the 
linguistic relationship of Finnish with languages spoken by certain ethnic groups in Russia, it 
has traditionally been thought that the Finns migrated to their current location from a common 
origin in the East, either in the Altai, the Ural, or the Volga region. Studies of nuclear gene 
frequencies, however, have shown that the greater proportion of the Finnish gene pool is 
"European", even though Finns appear to differ from other European populations more than 
Europeans in general differ from each other (Nei and Roychoudhury 1982, Virtaranta-Knowles 
et al 1991). Studies on mitochondrial DNA sequences have revealed that European populations, 
including Finns, are part of one homogeneous mitochondrial gene pool. Quite recently, 
however, y chromosome haplotype variation has provided evidence for a substantial paternal 
genetic contribution of Asians to the Finns (Zerjal et al 1997, Kittles et al 1998). 
6.1.2. Sensitivity of the sickness insurance register  
The Finnish nation-wide sickness insurance scheme covers the entire population. On the basis 
of the drug reimbursement register (a part of the Social Insurance Institution's population 
register), it is possible to estimate the occurrence of chronic rheumatic diseases. In a community 
with 18 000 inhabitants, 218 adult subjects with chronic rheumatic diseases had been registered 
for drug reimbursement and only two additional subjects with these disorders were found 
outside the register (Hakala et al 1993). In a nation-wide series of subjects with RA who had 
died in 1989, 95% of those in whom RA was mentioned in the death certificate had been 
entitled to specially reimbursed medication (Myllykangas-Luosujärvi et al 1995). Thus the 
sensitivity of the register as an inclusion criterion concerning patients with RA is good. Less 
information is available in the case of JIA. In a series of 47 pediatric patients, however, only 
one was not eligible for drug reimbursement (Savolainen and Isomäki 1993). 
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6.1.3. The study populations 
6.1.3.1. Population-based study of uveitis in juvenile idiopathic arthritis  
The incidence of JIA as assessed on the grounds of the drug reimbursement register was found 
to be 14/100 000 in the pediatric population (Kaipiainen-Seppänen and Savolainen 1996). This 
figure is in agreement with those in other studies from countries from which reliable 
information is available (Andersson Gäre 1999). 
The occurrence of uveitis was examined in this population-based cohort of JIA patients. All the 
114 JIA patients in this series (II) had been treated at their district central hospitals or at the 
Rheumatism Foundation Hospital, and accordingly patient records were readily available. The 
majority of these children had been examined by an ophthalmologist at the onset of JIA and 
thereafter one to two times a year for several years (43/114 patients were examined by the same 
ophthalmologist at the Rheumatism Foundation Hospital at least once). Evidently most, if not 
all, of the uveitis cases in the patient series could be identified. 
6.1.3.2. Uveitis in patients with a recent diagnosis of juvenile idiopathic arthritis  
The clinic-based study of uveitis in patients with recently diagnosed JIA (IV) was carried out at 
the Rheumatism Foundation Hospital, Heinola, Finland, where close co-operation with an 
ophthalmologist and pediatric rheumatologists is well organised (annually JIA patients require 
more than 1100 consultations with an ophthalmologist). As stated, the annual incidence of JIA 
in Finland is 14/100 000 (Kaipiainen-Seppänen and Savolainen 1996), this figure corresponding
to 150 new cases of JIA. One third of these are seen at the Rheumatism Foundation Hospital in 
the early phase of their disease and they have been examined by the ophthalmologist. The group 
is presumed to be representative of the newly diagnosed JIA patients from central parts of 
Finland. 
6.1.3.3. Uveitis in sibling pairs with juvenile idiopathic arthritis  
The genetic study series (III) comprised 80 JIA patients from 37 families with two or three JIA 
children. The index cases and the majority of their siblings were found among about 2000 JIA 
patients seen at the Rheumatism Foundation Hospital during a period of 15 years. In addition to 
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patients seen at the Hospital from the outset, there were also patients referred to the Hospital at 
a later phase because of sustained disease difficult to manage, for surgery, or for rehabilitation. 
Thus, the sibling series might have been to some degree selected. However, apart from their 
earlier age at onset, the siblings with JIA did not differ from JIA cases in the population based-
series (Säilä et al 2001). 
6.1.3.4. Uveitis as a cause of visual loss in arthritides and comparable conditions 
The role of rheumatic diseases or comparable conditions in the etiology of severe uveitis was 
examined on the basis of the Finnish Register of Visual Impairment. The register was founded 
in 1983 but remains incomplete. However, during recent years the annual number of new cases 
of visual handicap in different age groups has remained stable. The coverage is probably better 
for new cases than for those blinded decades earlier. It is reasonable to assume that young 
patients are recorded in the Register more frequently than older ones. On the other hand, due to 
the age wave, the proportion of senile macular degeneration is continuously increasing as a 
leading cause of visual handicap. In spite of its shortcomings, the register provided a basis for 
evaluation of visual loss caused by uveitis in rheumatic diseases and comparable conditions. 
The available patient records were checked. The information regarding patients blinded before 
1980 was often incomplete and thus only those whose visual loss was detected during the years 
1980 to 1996 were included in the study. 
6.2. Discussion of results
6.2.1. Occurrence of uveitis in juvenile idiopathic arthritis 
Most previous studies on uveitis in JIA come from special pediatric or ophthalmologic clinics, 
and the duration of follow-up periods has varied greatly. Only a few studies have been truly 
prospective (Spalter 1975, Chylack et al 1975, Michels et al 1987, Kanski 1988, Andersson 
Gäre and Fasth 1995). By far the largest series of JIA-associated uveitis was reported by Kanski 
(1988). It consisted of 315 clinic-based cases. Only a small proportion of the patients had been 
followed prospectively from onset but the vast majority of them were examined personally by 
the author. 
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Studies from ophthalmologic clinics tend to be biased toward the more severe cases of uveitis. 
Children with mild uveitis are frequently managed by ophthalmologists in the community, and 
only complicated, difficult-to-manage patients are referred to the academic centres. On the 
other hand, studies from pediatric clinics are similarly likely to be biased toward the more 
severe cases of arthritis. Only a few epidemiological surveys have been published (Towner et al 
1983, Kunnamo et al 1986, Andersson Gäre and Fasth 1995, Moe and Rygg 1998) and none of 
these has dealt with uveitis from an ophthalmologist's point of view. 
In the present study the occurrence of JIA-associated uveitis was examined on the basis of three 
different study series: population-based (II), genetic (III) and clinic-based (IV). Uveitis was 
found in 16%, 26% and 24% of patients, respectively. 
The clinic-based series was large enough to provide a reliable estimate of the frequency of 
uveitis (24.4%; 95% CI 20.3-28.5). The mean prospective follow-up period was 4.5 years 
(range 0-9.7 years), although for some cases it remained shorter. Although uveitis is detected in 
the great majority of JIA patients within the first five years of arthritis, in some cases it is a late 
manifestation. Due to the somewhat too short follow-up period the observed figure may 
underestimate the true occurrence of uveitis. On the other hand the ophthalmological 
consultations were regular and in the vast majority of cases conducted by the same 
ophthalmologist; thus, mild and even transient cases of uveitis could also promptly be found. 
The interval from the onset of arthritis to the emergence of uveitis in our series was among the 
shortest so far reported. In this context it is of interest to note that in another large clinic-based 
series from Finland with a mean follow-up as long as 15 years, 23% of the 173 JIA patients 
developed uveitis (Ylijoki 1998). 
The frequency of uveitis was somewhat lower (15.8%; 95% CI 9.1-22.5) in the population-
based series (II). However, due to the small number of cases it cannot be taken for granted that 
the found difference between the clinic and population studies was real. On the other hand, our 
figure is in agreement with those reported from northern Norway (14%) (Moe and Rygg 1998) 
and from south-western Sweden, where Andersson Gäre and Fasth reported figures of 9% and 
15% in their two groups of JIA patients (Andersson Gäre and Fasth 1995). Kunnamo and 
associates in their community-based study from the Helsinki area in Finland reported uveitis in 
21% of JIA patients. The total number of patients was small and the follow-up period was short 
(Kunnamo et al 1986). In another community-based study from Minnesota only 2 of 49 (4%) of 
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patients were reported to have uveitis (Towner et al 1986). However, not all patients had been 
examined by an ophthalmologist. In all the earlier community-based studies only figures 
concerning the occurrence of uveitis were reported. Our study II is unique in that ocular 
manifestations were managed from the point of view of an ophthalmologist. 
As pointed out in the literature review, there is some evidence that JIA associated-uveitis might 
occur less frequently in the USA than in England and the Scandinavian countries. In a recent 
large series from the Philadelphia area (Candell Chalom et al 1997) only 9% of patients had 
uveitis. The nucleus of the white population of the United States is from the British Isles. After 
the Civil War, however, most new migrants were from southern, south-eastern and eastern parts 
of Europe and in many areas offspring of these migrants outnumber those of the original 
settlers. No good figures are available from southern and eastern Europe on the occurrence of 
JIA and uveitis associated with it. Thus, it is not possible to draw conclusions as to the 
underlying reasons (genetic versus environmental) for the transatlantic difference in the 
occurrence of uveitis.
6.2.2. Determinants associated with development of uveitis in juvenile idiopathic arthritis. 
It is a common belief that uveitis in JIA is most frequent in ANA-positive girls with 
oligoarthritis, arising at ages between 2 and 4 years. Although in our clinic-based cohort of 426 
newly diagnosed JIA cases (IV) there were more girls than boys, uveitis was found 
proportionally as equally in both genders. Likewise, uveitis was associated as often with 
oligoarthritis as with polyarthritis. To study in greater detail the determinants associated with 
the development of uveitis we used a proportional hazard model for patients among whom 
uveitis had developed after the diagnosis of JIA. The only significant determinants for uveitis 
proved to be young age and ANA positivity. 
It has been assumed that genetic factors play only a modest role in the etiology of JIA. Our 
recent data, however, would indicate that the genetic component in JIA is more important than 
previously believed (Savolainen et al 2000). To assess the role of genetic factors specifically 
associated with the development of uveitis, we observed the occurrence and characteristics of 
uveitis in sibling pairs with JIA (III). Only three pairs were concordant for the presence of 
uveitis, the expected number being 3.4. The series reported by Clemens and colleagues (1985) 
consisted of 12 sibling pairs. Four of them were concordant for the presence of uveitis, and on 
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the basis of data given in their paper the expected number was 2.5. Moroldo and associares 
(1997) reported on a total of 71 sibling pairs. Three pairs were concordant, the expected number 
was 1.3. Taken together, the data gathered lend little support for the concept of an appreciably 
heightened sibling recurrence ratio in the etiology of uveitis. 
The exact relationship between uveitis and JIA is not known. HLA B27-associated acute 
anterior uveitis occurs not infrequently in conjunction with symptoms and signs of 
spondyloarthropathy. However, perhaps even in the majority of patients with this type of uveitis 
there is no evidence of an underlying rheumatic disease (Rothova et al 1987, Huhtinen and 
Karma 2000). The association of uveitis and JIA is closer. For example, in a Finnish-population 
based survey of uveitis in children the uveitis cases associated with JIA outnumbered those with 
"idiopathic" chronic anterior uveitis (Päivönsalo-Hietanen et al 2000). 
6.2.3. Complications and treatment of uveitis in juvenile idiopathic arthritis
The most common complications in our series were cataract, glaucoma, CME and band 
keratopathy. Of these, band keratopathy always results from inflammation, whereas cataract 
and glaucoma can also result from treatment, and CME from surgery, e.g. cataract extraction. In 
this regard it is of interest to note that as many as 14% of JIA patients without uveitis in our 
clinic-based series (IV) developed cataract; all had received systemic corticosteroids, whereas 
none of those who had not received systemic corticosteroids developed cataract. None of the 
patients without uveitis had glaucoma. In the long-term follow-up study of JIA patients by 
Ylijoki (Ylijoki 1998), 4 of 173 patients had impaired vision. In two cases this was attributable 
to uveitis and in two cases to cataract induced by corticosteroid treatment. 
During the last 20 years the prognosis of JIA patients has improved as a result of effective 
medical and surgical treatment of the arthritis and better treatment of severe uveitis (Cabral et al 
1994, Tugal-Tutkun et al 1996, Dana et al 1997, Nguyen and Foster 1998) (Table 12).  
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Table 12. Decreasing severity of uveitis in patients with JIA and uveitis 
 Cassidy 
et al 
 1977 
Wolf 
et al 
 1987 
Cabral
et al 
1994
Candell Chalom 
et al  
1997
Kotaniemi 
et al  
2001
Number of patients, n 
(Affected eyes, n) 
38 51 
(89)
49
(82)
71 104 
(170)
Mean follow-up, years 4.8 12.7 9.4 NA 5.8 
Visual impairment (<20/50)  
     Patients, n (%)
     Eyes, n (%) 
14 (37) 
35 (39) 12 (15) 
8 (11) 4 (4) 
8 (5) 
Abbreviation: NA, not available 
It is possible that the combination of corticosteroids with methotrexate and/or cyclosporine (I) 
or azathioprine or other immunosuppressive medications has made for improved visual 
prognosis in uveitis patients.  
In the present clinic-based series (IV) complicating cataract was found in 22 of 104 JIA patients
with uveitis and it was operated in nine cases (intraocular lens implantation in six). 
New cataract surgery techniques are helpful in visual rehabilitation of children with JIA, but the 
role of intraocular lens implantation in uveitic eyes is still controversial (Foster and Barrett 
1993, BenEzra and Cohen 2000). It is recommended to concentrate surgery on JIA children 
with uveitis in experienced hands (Kanski and Petty 1996, Nguyen and Foster 1998).  
Secondary glaucoma is often refractory to medical treatment. Operative treatment of glaucoma 
has also altered during the last 20 years; glaucoma implant devices have shown good results in 
JIA in cases with secondary glaucoma refractory to medical treatment (Välimäki et al 1997). In 
the series of 104 JIA patients with uveitis here (IV), a glaucoma operation was needed in three 
cases (with a filtering implant device in two). In some children secondary glaucoma can be 
managed with laser treatment and/or conventional filtering surgery with or without local 
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antimetabolites (e.g. fluorouracil or mitomycin). The operative treatment should not be 
postponed too far (Kanski and Petty 1996). 
CME is a severe complication of uveitis and must be treated promptly and actively. Systemic 
corticosteroids and/or local corticosteroid injections are the first choice, but good control of 
uveitis in the long run is mandatory. In sight-threatening situations the use of 
immunosuppressive and immunomodulatory drugs must be considered (Nguyen and Foster 
1998).
The prevalence of severe band keratopathy in our study (IV) was lower than previously 
reported, which may reflect earlier detection and more effective present treatment of uveitis 
than two decades ago (Sherry et al 1991). 
In fact, during earlier decades the visual prognosis of patients with uveitis has been markedly 
poorer than at present (Kanski 1977, 1981, Cabral et al 1994). Nevertheless, our study based on 
the Finnish Register of Visual Impairment in 1980-1996 (VI) showed that uveitis caused 3% of 
visual impairment and the most prominent single group (14 out of 174 cases) comprised 
patients with JIA- associated uveitis. Also in a Dutch study of the causes of blindness in 
patients with intraocular inflammatory diseases, JIA was the most frequent systemic disease 
leading to visual handicap (Rothova et al 1996), the second being sarcoidosis. 
6.2.4. Association of uveitis and arthritis in juvenile idiopathic arthritis. 
It is commonly thought that uveitis and arthritis in JIA run a different course and that the 
articular prognosis of children with oligoarthritis is good (Rosenberg and Oen 1986, Kanski and 
Petty 1996). Our conception is that uveitis is a part of the disease process rather than a 
complication of JIA; accordingly the treatment of uveitis should follow the same rules as that of 
JIA. In clinical work one gets an impression that JIA children with refractory uveitis frequently 
also have very active arthritis and improvement in uveitis - as in the case of our patient (I) - is 
achieved only through the control of arthritis.  
To our knowledge only one study hitherto has specifically addressed the question of the 
articular prognosis of JIA patients with uveitis (Cimaz and Fink 1996). In the study in question 
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29 patients with uveitis and 86 control cases were compared. There too the patients with uveitis 
managed worse regardless which one of the four indicators was applied. 
We studied the association between the clinical activity of arthritis and the occurrence of uveitis 
by utilising our large cohort of 372 seronegative (out of a total of 426) newly diagnosed JIA 
patients with oligoarthritis or polyarthritis (V). ESR and CRP values, the routinely used 
laboratory acute-phase measures mirroring clinical disease activity, were statistically 
significantly higher in JIA patients with uveitis than in cases without. The number of inflamed 
joints was significantly greater at the end of the follow-up in patients with persistent 
polyarthritis and uveitis compared to those polyarthritis patients without uveitis. Further, 
methotrexate and systemic corticosteroid treatment as well as the need of local corticosteroid 
joint injections were more frequent in the group of patients with uveitis.
As discussed above, the present series may be taken to be fairly representative of recently 
diagnosed cases of JIA from central parts of Finland and in our opinion the observed 
association between the severity of arthritis and uveitis is genuine and not a consequence of 
biased patient selection. 
6.2.5. Uveitis as a cause of visual loss in arthritides and comparable conditions. 
The etiology of blinding uveitis was examined using information from the Finnish Register of 
Visual Impairment. Special problems occur with uveitis. Its sequelae such as cataract and 
glaucoma may be considered the cause of visual loss while the primary cause (uveitis) has not 
been mentioned (Rothova et al 1996). This error is likely to occur more frequently in idiopathic 
uveitis cases than in those with established etiology or with well-known disease associations.
Chronic insidious uveitis is a prominent manifestation of JIA. It is usually bilateral and 
asymptomatic. If not detected early and properly treated, it can result in substantial morbidity 
and even blindness (Rothova et al 1987, Kanski 1990, Candell Chalom et al 1997, Dana et al 
1997).
Uveitis occurring in conjunction with the HLA B27 allele is a distinct clinical entity 
characterised typically by acute, unilateral, recurrent attacks of iridocyclitis (Wakefield et al 
1991, Rodriguez et al 1994). This allele occurs in Finns more frequently (14%) than in most 
other populations of European origin. Occasionally, the inflammation becomes chronic, 
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resulting in sight-impairing complications (cataract, glaucoma, CME and band keratopathy). 
There is occasional evidence that severe eye disease is more likely to accompany reactive 
arthritis than ankylosing spondylitis (Youssef and Russell 1990, Rodriguez et al 1994, Calin 
1998). To our knowledge, however, no patient series has been published. 
A rheumatic disease or comparable condition was found in the etiology of severe uveitis in 22% 
in our series of 174 uveitis patients with visual loss established during 1980-1996; earlier cases 
were excluded. Thus, this material constitutes a cumulative incidence series rather than a 
prevalence series. About one-third of the patients had some rheumatic complaints. JIA was the 
most prominent group, consisting of 14 patients, all of whom had longstanding disease. Most 
likely the diagnosis of uveitis in these patients had been delayed.  
The four patients diagnosed as having seronegative RA may equally well have been suffering 
from spondyloarthropathy with predominant peripheral joint involvement. On the other hand, 
one of these patients had most probably contracted her disease before the age of 16 and could 
thus be classified in the JIA group as well. Further, some of the cases with ill-defined back 
problems may also have been suffering from spondyloarthropathy. Interestingly, in half of the 
patients with spondyloarthropathies uveitis was insidious at onset and ran a chronic course 
instead of being acute and symptomatic. This is obviously due to selection of patients with poor 
prognosis of their rheumatic disease in this cohort. 
The number of patients with sarcoidosis was appreciably lower than that of patients with JIA 
and spondyloarthropathies. In this respect our study differs from an earlier report where 
sarcoidosis was among the most frequent causes of blinding uveitis (Rothova et al 1996). 
Most of the uveitis patients in the present series represent treatment failures from a period prior 
to 1980. Systematic screening for patients with JIA was instituted in Finland in the late 1970s. 
However, the prognosis of uveitis is considered to be better today than it was a few decades ago 
owing to effective medication and better conventional and surgical treatment of both arthritis 
and uveitis. 
Our study provides population-based data on visual handicap associated with different uveitis 
entities. The importance of the search for the etiology of the systemic disease associations of 
uveitis cannot be overestimated.
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7. RECOMMENDATIONS CONCERNING THE 
SCREENING AND MANAGEMENT OF UVEITIS 
ASSOCIATED WITH JUVENILE IDIOPATHIC  
ARTHRITIS 
Uveitis in JIA is frequently chronic and the treatment remains unsatisfactory (I). In early phases 
it is difficult to detect the few small cells in the anterior chamber or faint aqueous flare in a 
poorly cooperating child. Repeated control examinations are technically easier to carry out if 
the ophthalmologist and the staff are familiar with child and parents. On the other hand, through 
repeated re-examinations during follow-up the ophthalmologist becomes acquainted with the 
individual features of uveitis in each patient, which facilitates the planning of management in 
the long run. 
The mainstay in the treatment of uveitis is the strict control of inflammation. Therapy is 
discontinued step by step and the eyes have to be repeatedly re-examined, since prompt 
observation of a relapse and reinstitution of therapy is a must. The timely treatment of 
complications of uveitis, cataract and glaucoma, is important. Corticosteroid treatment has to be 
balanced delicately, since both uveitis as a process, but also corticosteroids given as therapy are 
cataractogenic. This concerns especially children with systemic onset JIA, who are frequently 
treated with large doses of corticosteroids for months or even years and thus are at an increased 
risk of developing cataract.  
The phacoemulsification of the cataract with intracapsular lens implantation combined with 
anterior vitrectomy and opening of the posterior capsule via the pars plana is a method 
frequently used today. The cataract operation should not be postponed too far, in view of the 
risk of amblyopia. The visualisation of the fundus of the eye is also important in order to find 
possible complicating CME in time, as well as to evaluate the optic disc for possible 
glaucomatous changes.  
Medical treatment of uveitis-associated secondary glaucoma is often unsuccessful. 
Cyclodestruction with cryo- or laserapplication may result in the control of glaucoma, as well 
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as other surgical methods such as trabeculectomy and filtering phlebs. One must not forget that 
about 10% of persons are corticosteroid responders; increased ocular pressure is a consequence 
of local, or to a lesser extent of systemic corticosteroid treatment.  
Aggressive treatment of both arthritis and uveitis from the very beginning of the joint and eye 
disease would appear to be important. The fear of side-effects of the drugs ought not to be an 
obstacle to effective treatment if the uveitis is sight-threatening. From a clinician's perspective, 
active arthritis seems to be associated with ongoing uveitis (V). Continuous monitoring of such 
cases by experienced ophthalmologists in close co-operation with pediatric rheumatologists is 
essential in saving the sight of these patients. (Nguyen and Foster 1998).  
Careful ophthalmologic screening for uveitis in children with JIA is 
recommended: 
1. Every 3-4 months in early-onset oligoarthritis or RF-negative polyarthritis for the first 
two years, then twice yearly until the age of 16, then every 2nd-3rd year for several 
years. 
2. Twice a year in RF-positive polyarthritis and systemic onset JIA until the age of 12, 
then yearly until the age of 16. 
3. Young children (<4 years) with ANA-positive oligoarthritis or polyarthritis run the 
greatest risk of contracting uveitis. They should be regularly examined by an 
experienced ophthalmologist at least four times a year two years and then twice a year 
for the first four years of arthritis. 
4. Children with active and refractory uveitis and arthritis should be monitored by the 
same team of ophthalmologists and pediatric rheumatologists in order to establish 
optimal management for both arthritis and uveitis of each individual. 
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